



(51) International Patent Classification:

A61N 1/00 (2006.01) C23C 26/00 (2006.01)  
A61N 1/05 (2006.01) B05D 5/12 (2006.01)  
A61N 1/39 (2006.01) A61B 5/04 (2006.01)  
A61F 2/02 (2006.01)

(21) International Application Number:

PCT/IL2014/050994

(22) International Filing Date:

17 November 2014 (17.11.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/905,230 17 November 2013 (17.11.2013) US

(71) Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD. [IL/IL]; P.O. Box 39296, 6139201 Tel-Aviv (IL).

(72) Inventors: DVIR, Tal; c/o Ramot at Tel-Aviv University Ltd., P.O. Box 39296, 6139201 Tel-Aviv (IL). SHACHAM-DIAMAND, Yosi; c/o Ramot at Tel-Aviv University Ltd., P.O. Box 39296, 6139201 Tel-Aviv (IL). FEINER, Ron; c/o Ramot at Tel-Aviv University Ltd., P.O. Box 39296, 6139201 Tel-Aviv (IL). ENGEL, Leeya; c/o Ramot at Tel-Aviv University Ltd., P.O. Box 39296, 6139201 Tel-Aviv (IL).

(74) Agents: EHRLICH, Gal et al.; G.E. EHRLICH (1995) LTD., 11 Menachem Begin Road, 5268104 Ramat Gan (IL).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: ELECTRONIC SCAFFOLD AND USES THEREOF



(57) Abstract: A device comprising a three-dimensional polymeric element and an electronic element integrated with the polymeric element is disclosed. The electronic element is made up of one or more electrode(s) each individually connectable to a measuring device and/or a controller, and each independently having a thin electrically-isolating layer deposited thereon such that the electrode is exposed to an environment surrounding the electrode at one or more pre-determined locations over the electrode. The device can include cells and/or tissue and/or a therapeutically active agent incorporated within the polymeric material. Processes of fabricating the device, systems for operating the device and methods utilizing same are also disclosed.



## ELECTRONIC SCAFFOLD AND USES THEREOF

FIELD AND BACKGROUND OF THE INVENTION

The present invention, in some embodiments thereof, relates to tissue  
5 engineering and, more particularly, but not exclusively, to an electronic scaffold,  
engineered tissue made therefrom and uses thereof.

About 8 million people in the United States suffer from a myocardial infarction  
(MI) during their lifetime, with about 800,000 new cases occurring each year.  
However, despite its prevalence, conventional therapies of MI remain limited by the  
10 inability of the myocardium to regenerate after injury and the shortage of donor organs  
that are available for transplantation. MI therefore continues to be a degenerative  
disease with a peak of cell death occurring at the onset of the infarction and also  
continuing thereafter. Cell-based therapies or tissue engineering approaches have been  
recognized as viable approaches to improve healing after a MI and restore the function  
15 of cardiac tissue.

Cardiac tissue engineering (CTE) has emerged as a promising treatment for  
replacing the scar tissue formed after myocardial infarction. Engineered cardiac patches  
to replace scar tissue after myocardial infarction can be produced by seeding cardiac  
cells within porous three dimensional ("3D") biomaterials, which provide mechanical  
20 support while cells organize into a functioning tissue.

Improving the viability, ultrastructural morphology and functionality of  
engineered cardiac tissue has been addressed by growing cell constructs in advanced  
bioreactors providing high mass transfer or exposing the tissues to electrical (Radisic, M  
et al. *Proc. Natl. Acad. Sci. USA* 101, 18129-18134 (2004)) and mechanical cues  
25 (Zimmermann, W.H., et al. *Circ. Res.* 90, 223-230 (2002); Dvir, et al. *Tissue Eng.* 13,  
2185-2193 (2007)). Scaffold structural and mechanical properties can be improved by  
microfabrication processes that provide controllable stiffness and anisotropy  
(Engelmayr, G.C., et al. *Nature Mat.* 7, 1003-1010 (2008)).

WO 2012/194208 discloses incorporating electrically conductive nanowires  
30 within scaffolds, to enhance tissue growth, bridge the electrically resistant pore walls  
and improve electrical communication between adjacent cardiac cell bundles.

WO 2013/109642 discloses a nanofiber structure featuring a basketweave configuration, which is made by electrospinning a biodegradable polymer and weaving strips of the electrospun nanofibers.

5 Dvir et al., 2011, Nature nanotechnology 6, 720-725, teaches embedding of gold nanowires within the pore walls of macroporous alginate scaffolds to increase the spatial and overall conductivity of the matrix. When cardiac cells were cultured in these nanowired scaffolds they exhibited increased expression of contractile and electrical coupling proteins.

10 You et al, 2011, Nano letters 11, 3643-3648 teaches cardiomyocytes cultured in hybrid hydrogel scaffolds based on spherical gold NPs, homogeneously distributed throughout a polymeric gel. The cells exhibited increased expression of connexin 43, a protein located between cardiac cells, responsible for electrical signal transfer.

15 Additional background art includes Tian et al., Nature Materials, Vol. 11, November 2012, pp. 986-994; Fleischer et al., Biotechnology and Bioengineering Volume 111, Issue 6, pages 1246–1257, June 2014; WO 2005/007233; PCT/IL2014/050445; Prabhakaran et al., 2011, Journal of nanoscience and nanotechnology 11, 3039-3057; Whelove et al., 2011, J Biomed Mater Res Part B 2011:99B:142–149; Karni et al., Nano letters, 2012, 12(10), 5403-5406; Shan-hui Hsu Biomacromolecules 2008, 9, 241–248; Prabhakaran et al., 2012, Biopolymers Volume 20 97, 7, pages 529-538; Fleischer et al., Biomaterials, 2013, 34(34), 8599-8606; and U.S. Patent Application having Publication No. 20100106233.

Currently known methodologies of CTE are limited by the inability to monitor and control the engineered tissue's performance after transplantation.

## 25 SUMMARY OF THE INVENTION

The present invention, in some embodiments thereof, relates to tissue engineering and, more particularly, but not exclusively, to an electronic scaffold, engineered tissue made therefrom and uses thereof.

30 The present invention, in some embodiments thereof, relates to a scaffold device comprising a scaffold element made of a polymeric material (three-dimensional polymeric element), integrating an electronic element (e.g., a microelectronic element), to an engineered tissue made therefrom by incorporating and cultivating cells in the scaffold element, to systems for operating the device and/or the engineered tissue and to

utilizing the device and/or the engineered tissue, optionally by means of the disclosed system, in monitoring (e.g., recording) function and/or activity (e.g., electrical activity) of a cell or a tissue; in stimulating a function and/or activity (e.g., electrical activity) of a cell or a tissue; in effecting and/or controlling drug release from the device and/or  
5 engineered tissue; and in studying the effect (e.g., toxicity or efficacy) of a drug on a cell or a tissue.

According to an aspect of some embodiments of the present invention there is provided a scaffold device comprising: a three-dimensional polymeric element (a scaffold element); and an electronic element being integrated with (or being in contact  
10 with) the polymeric element, the electronic element comprising at least one electrode being connectable to a measuring device and/or a controller, the electrode having an electrically-isolating layer deposited thereon such that a portion of the electrode remains partially uncoated in at least one location and is exposed to an environment surrounding the electrode at the at least one location.

15 According to some embodiments of the present invention, the electrode is exposed to the environment at a tip of the electrode.

According to some embodiments of the present invention, the electrode is exposed to the environment at a plurality of discrete locations over the electrode.

20 According to some of any of the embodiments of the present invention, the thin electrically-isolating layer is an electrically-isolating polymeric layer.

According to some of any of the embodiments of the present invention, the electrically-isolating polymeric layer comprises an epoxy photoresist and/or a polyimide.

According to some of any of the embodiments of the present invention, the thin electrically-isolating layer has a thickness that ranges from 0.1 micron to 100 microns.

25 According to some of any of the embodiments of the present invention, at least one dimension of the electrode ranges from 1 micron to 1000 microns.

According to some of any of the embodiments of the present invention, the at least one electrode has a shape of a straight line.

30 According to some of any of the embodiments of the present invention, the at least one electrode has a shape of a curved line.

According to some of any of the embodiments of the present invention, the at least one electrode is elastic.

According to some of any of the embodiments of the present invention, the at least one electrode has a generally constant conductivity as a function of a strain exhibited by the at least one electrode.

According to some of any of the embodiments of the present invention, the  
5 electronic element comprises a plurality of electrodes, each being individually connectable to a measuring device and/or a controller, and each independently having a thin electrically-isolating layer deposited thereon such that a portion of the electrode remains partially uncoated in at least one location and is exposed to the environment surrounding the electrode at the at least one location.

10 According to some of any of the embodiments of the present invention, the controller is configured for transmitting stimulation signals through the electrode.

According to some of any of the embodiments of the present invention, the device further comprises a miniature power source mounted in proximity to the electronic element.

15 According to some of any of the embodiments of the present invention, the measuring device is configured for measuring signals transmitted from the polymeric element through the electrode.

According to some of any of the embodiments of the present invention, the measuring device is configured for measuring signals transmitted from the environment  
20 through the electrode.

According to some of any of the embodiments of the present invention, the polymeric element comprises an electrospun fibrous polymeric material.

According to some of any of the embodiments of the present invention, the polymeric material comprises at least one of albumin, a polycaprolactone (PCL), gelatin,  
25 a poly(lactic acid) (PLA), a poly(lactic acid-co-glycolic acid) (PLGA), decellularized extracellular matrix and any combination thereof.

According to some of any of the embodiments of the present invention, polymeric material comprises a polycaprolactone (PCL) and gelatin.

According to some of any of the embodiments of the present invention, the  
30 polymeric material comprises albumin.

According to some of any of the embodiments of the present invention, the polymeric element comprises an electro-responsive polymeric material.

According to some of any of the embodiments of the present invention, the device further comprises cells incorporated in and/or on the polymeric element.

According to some of any of the embodiments of the present invention, the cells form a tissue.

5 According to some of any of the embodiments of the present invention, the device further comprises a therapeutically active agent incorporated in and/or on the polymeric element.

10 According to some of any of the embodiments of the present invention, the polymeric element comprises an electro-responsive polymer and a therapeutically active agent is associated with the electro-responsive polymeric material via electrostatic interactions.

According to some of any of the embodiments of the present invention, a scaffold device as described herein is usable for being implanted in or on a tissue or an organ of a subject in need thereof.

15 According to some of any of the embodiments of the present invention, a scaffold device as described herein is usable for monitoring and/or stimulating an activity and/or a function of a cell and/or a tissue.

According to some of any of the embodiments of the present invention, the cell or the tissue is incorporated in the polymeric element.

20 According to some of any of the embodiments of the present invention, the scaffold device as described herein is usable for monitoring and/or stimulating an activity and/or a function of the cell or the tissue *in vivo*.

25 According to some of any of the embodiments of the present invention, a scaffold device as described herein is usable for controlling a release of a therapeutically active agent from a polymeric element.

According to some of any of the embodiments of the present invention, a scaffold device as described herein is usable for determining a toxicity or an efficacy of a therapeutically active agent to a cell or tissue.

30 According to some of any of the embodiments of the present invention, the determining comprises: providing a device comprising a therapeutically active agent as described herein, in which a cell or a tissue is incorporated in the polymeric element; monitoring a function or activity of a cell or a tissue incorporated in the polymeric

element; and comparing the monitored function or activity of the cell or the tissue with a function or activity of the cell or the tissue without a therapeutically active agent, thereby determining a toxicity or an efficacy of the therapeutically active agent to the cell or the tissue.

5           According to an aspect of some embodiments of the present invention there is provided a method of determining a toxicity or an efficacy of a therapeutically active agent to a cell or tissue, wherein the determining is effected as described herein.

          According to an aspect of some embodiments of the present invention there is provided a system comprising the device as described in any one of the embodiments  
10       herein, and any combination thereof, and at least one electric device selected from the group consisting of a controller and a measuring device.

          According to an aspect of some embodiments of the present invention there is provided a method of implantation, comprising: implanting a scaffold device comprising a cell or a tissue associated with the scaffold element, as described herein in any one of  
15       the respective embodiments, in an organ; and receiving electrical signals from the cells via the electronic element.

          According to some of any of the embodiments of the present invention, the scaffold device further comprises a therapeutically active agent incorporated in the polymeric element, the method comprising transmitting stimulating signals via the  
20       electronic element so as to controllably release the therapeutically active agent from the polymeric element.

          According to some of any of the embodiments of the present invention, the cells are responsive to electrical stimulation and the method comprising transmitting stimulating signals via the electronic element so as to stimulate the cells.

25           According to an aspect of some embodiments of the present invention there is provided a method of implantation, comprising: implanting a scaffold device in an organ, the scaffold device comprising a therapeutically active agent, as described in any one of the respective embodiments; and transmitting stimulating signals via the electronic element so as to controllably release the therapeutically active agent from the  
30       polymeric element.

          According to an aspect of some embodiments of the present invention there is provided a method of implantation, comprising: implanting a scaffold device in an

organ, the scaffold device comprising a cell or a tissue in association with the scaffold element, as described herein in any one of the respective embodiments, wherein the cells are responsive to electrical stimulation; and transmitting stimulating signals via the electronic element so as to stimulate the cells.

5           According to some of any of the embodiments of the present invention, the cells are cardiac cells and the organ is a myocardium.

          According to some of any of the embodiments of the present invention, the signals are selected for pacing the myocardium.

          According to some of any of the embodiments of the present invention, the cells  
10 are liver cells and the organ is a liver.

          According to an aspect of some embodiments of the present invention there is provided a method of treating a disease or disorder caused by dysfunction in, or damage to, an excitable tissue in a subject in need thereof, the method comprising transplanting a scaffold device comprising a cell and/or a tissue and/or a therapeutically active agent, as  
15 described herein in any one of the respective embodiments, in the subject.

          According to an aspect of some embodiments of the present invention there is provided a scaffold device as described herein, for use in a method of treating a disease or disorder, as described herein in any one of the respective embodiments, and any combination thereof.

20           According to some of any of the embodiments of the present invention, the disorder is a cardiac disorder associated with a defective or absent myocardium, and/or characterized by abnormal cardiac rhythm.

          According to further aspects of some embodiments of the present invention, there are provided uses of a scaffold device as described herein, in any one of the  
25 methods as described herein, and any respective embodiment or combination of embodiments thereof.

          Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those  
30 described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent



specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.

Implementation of the method and/or system of embodiments of the invention can involve performing or completing selected tasks manually, automatically, or a combination thereof. Moreover, according to actual instrumentation and equipment of  
5 embodiments of the method and/or system of the invention, several selected tasks could be implemented by hardware, by software or by firmware or by a combination thereof using an operating system.

For example, hardware for performing selected tasks according to embodiments  
10 of the invention could be implemented as a chip or a circuit. As software, selected tasks according to embodiments of the invention could be implemented as a plurality of software instructions being executed by a computer using any suitable operating system. In an exemplary embodiment of the invention, one or more tasks according to exemplary  
15 embodiments of method and/or system as described herein are performed by a data processor, such as a computing platform for executing a plurality of instructions. Optionally, the data processor includes a volatile memory for storing instructions and/or data and/or a non-volatile storage, for example, a magnetic hard-disk and/or removable  
20 media, for storing instructions and/or data. Optionally, a network connection is provided as well. A display and/or a user input device such as a keyboard or mouse are optionally provided as well.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the  
25 drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.

In the drawings:

30 FIGs. 1A-B present schematic illustrations describing an operation principle of an exemplary system according to some embodiments of the present invention (FIG. 1A) and an exemplary scaffold device according to some embodiments of the present

invention (FIG. 2B), comprised of e.g., gold electrodes having deposited thereon electro-responsive polymeric material loaded with one or more therapeutically active agent(s) (e.g., drug and/or growth factors) and integrated with a 3D scaffold element (left illustration), whereby cardiac cells are associated with the scaffold element, as depicted in the top right illustration, and the entire device is engaged with the heart as a cardiac patch (bottom right illustration).

FIGs. 2A-B present photographs of an exemplary electronic element of a device according to some embodiments of the invention, made of a gold electrode and a SU-8-based polymeric layer, released from the wafer utilized in its preparation, and before integration with a scaffold element to form the device.

FIG. 3 presents a microscope image of an exposed tip of a gold electrode in an electronic element as described in Figures 2A-B, according to exemplary embodiment of the present invention.

FIG. 4 presents an image of an exemplary device according to some embodiments of the present invention after depositing on the electronic element PCL/Gelatin nanofibers by electrospinning.

FIGs. 5A-B presents scanning electron micrographs (SEMs) of exemplary devices according to some embodiments of the present invention, showing a gold electrode coated by a SU-8-based polymeric layer and covered by PCL/gelatin fibrous scaffold element (FIG. 5A) and by albumin fibrous scaffold element (FIG. 5B).

FIG. 6 presents an image of an exemplary device comprising an electronic element and PCL/gelatin scaffold and seeded with cardiomyocytes.

FIGs. 7A-B present a fluorescent microscope image of rat neonatal ventricular cardiomyocytes seeded on a device as presented in FIGs. 5A and 6 (FIG. 7A) and on a device as presented in FIG. 5B (FIG. 7B).

FIG. 8 presents an exemplary system set up for electrical signal readings using a device according to some embodiments of the present invention.

FIG. 9 is a photograph showing subcutaneous implantation of an engineered (cyborg) tissue according to some embodiments of the present invention into a Sprague-Dawley rat.

FIG. 10 is a photograph showing recording action potentials and actuating the implanted engineered (cyborg) tissue, upon sedating the animal and connecting it to a pre-amplifier.

FIGs. 11A-B present action potentials recorded from a single (FIG. 11A) and  
5 multiple (FIG. 11B) electrodes in an *in vitro* experiment using an exemplary engineered (cyborg) tissue according to some embodiments of the present invention, as presented in FIG. 7B.

FIG. 12 presents action potentials recorded from a single electrode of a device cultured with neonatal rat ventricular cardiomyocytes, as presented in FIG. 7B, before  
10 (top) and after (bottom) adding a stimulating drug (Noradrenalin).

FIGs. 13A-B present the data obtained in measurements for evaluating the influence of electrical stimulation from a device as presented in FIG. 7B, incubated with a fluorescent calcium probe that fluoresces when the tissue contracts, showing images of the tissue before stimulation (FIG. 13A) and after the tissue was stimulated at a 1 Hz  
15 pace from within the device (FIG. 13B).

FIG. 14 presents a schematic illustration of a device, according to some embodiments of the present invention, in which the three dimensional polymeric element is formed from an electro-responsive polymer, which has a drug bound thereto via electrostatic interactions, whereby the drug is released when electric power (e.g.,  
20 potential) is applied.

FIGs. 15A-B present a SEM image of an exemplary bare electronic element according to the present embodiments before (top image) and an image obtained by fluorescent microscopy (bottom image) after deposition of PolyAMPS-containing copolymer loaded with Fluorescein (FIG. 15A), and a graph showing a release profile of dopamine from a PolyAMPS-containing scaffold, as measured by optical density (FIG.  
25 15B).

FIG. 16 presents a scanning electron micrograph (SEM) of a polypyrrole hydrogel deposited on a gold electrode having a TiN layer.

FIG. 17 presents a graph showing the release profile of SSA from a polypyrrole  
30 hydrogel, upon application of electrical power (on).

FIG. 18 presents a profile measurement of TiN layer deposited on gold electrodes, according to exemplary embodiments of the present invention.

FIG. 19 is a bar graph showing the conductance of an exemplary electronic element according to some embodiments of the present invention, as a function of the radius of curvature.

FIG. 20 presents a schematic illustration of an electronic element featuring a curled morphology which can be stretched, according to some embodiments of the present invention.

FIG. 21 presents comparative plots showing the effect of the drying method of the release profile of dopamine from a PolyAMPS-containing, hydrogel by diffusion.

FIG. 22 presents comparative plots showing the effect of the drying method of the release profile of dopamine from the dried a PolyAMPS-containing hydrogel upon electric stimulation.

FIG. 23 presents a graph showing the long-term release profile of dopamine upon electric stimulation, from a PolyAMPS-containing hydrogel dried by lyophilization.

FIG. 24 presents comparative plots showing the release profile of dopamine from a PolyAMPS-containing hydrogel dried by lyophilization as a function of the applied potential.

FIG. 25 presents a bar graph showing the swelling degree of a PolyAMPS-containing hydrogel as a function of the molar ratio of cross linker and initiator used during gel polymerization.

FIG. 26 presents a bar graph showing the amount of dopamine loaded into a PolyAMPS-containing hydrogel as a function of the initiator/cross-linking agent molar ration.

FIG. 27 presents a bar graph showing the effect of the drying method on the swelling capacity of a PolyAMPS-containing hydrogel.

FIG. 28 is a schematic illustration of a scaffold device according to some embodiments of the present invention.

FIGs. 29A-B are schematic illustrations of an electrode according to some embodiments of the present invention.

FIG. 30 is a schematic illustration of a system for controlling, treating and/or extracting information from cells and/or tissues incorporated in and/or on a scaffold element in a device according to some embodiments of the present invention.

DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION

The present invention, in some embodiments thereof, relates to tissue engineering and, more particularly, but not exclusively, to an electronic scaffold, engineered tissue made therefrom and uses thereof.

5        Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details of construction and the arrangement of the components and/or methods set forth in the following description and/or illustrated in the drawings and/or the Examples. The invention is capable of other embodiments or of being practiced or carried out in various  
10        ways.

The present inventors have devised and successfully prepared and practiced a scaffold device (herein also referred to as “an electronic scaffold”) which can be used for establishing communication between an electronic circuit and a biological material. The scaffold device can be employed in many applications, including, without  
15        limitation, implantation in the body of a subject, e.g., a mammalian subject, for example, as an engineered tissue; monitoring and/or stimulation of an activity and/or a function of a cell (e.g., a tissue cell), either *in vivo* or *in vitro*; control release of an agent, e.g., a therapeutically active agent; and/or screening of chemical or biological agents, so as, for example, determining a toxicity or efficacy of therapeutically active  
20        agents.

Herein throughout, a “biological material” is meant to include a cell, cells and/or a tissue.

In some embodiments of the present invention the scaffold device is used for tissue engineering. For example, the scaffold device can be used for engineering a  
25        cardiac patch, e.g., for the purpose of replacing a scar tissue formed on the heart after heart attack. The scaffold device can optionally and preferably facilitates pacing, monitoring and/or releasing drugs in the engineered tissue (e.g., cardiac patch).

The scaffold device can be used for measuring action potentials, e.g., in natural or engineered cardiac and neuronal tissues. The scaffold device can also serve as, or be  
30        a component of a pacemaker.

While some of the embodiments below are described with a particular emphasis to cardiac tissue, it is to be understood that more detailed reference to cardiac tissue is

not to be interpreted as limiting, and that the present embodiments also contemplate use of the scaffold device for engineering, and/or monitoring and/or stimulating and/or treating other tissues such as, but not limited to, liver tissue. The scaffold device of the some embodiments can also be used for monitoring cell secretions, such as albumin.

5           In some embodiments, the scaffold device is used to make up a final product such as, for example, a cyborg tissue ready for implant into a patient. A patient can be, for example, one who has suffered from a myocardial infarction and needs to treat the necrotic tissue. The engineered (cyborg) tissue is implanted on the heart with a miniature wireless power source and monitored and controlled from outside. The  
10 scaffold device of the present embodiments can then be used, e.g., to monitor heart function, provide electrical support as a pacemaker, and/or release therapeutically active agents (e.g., drugs or factors) in a controlled manner.

The scaffold device optionally and preferably comprises an electronic element and a three-dimensional polymeric element associated therewith. The electronic  
15 element and the scaffold element can be integrated together, for example, by embedding the electronic element into the scaffold element, depositing the scaffold element on or around the electronic element, and/or be attached to each other, for example, in a layerwise manner.

In some embodiments, the electronic element serves for establishing  
20 communication between the electronic circuit and the scaffold element and/or cells or tissues associated with scaffold element, and the scaffold element serves for establishing communication between cells or tissues and the electronic element. The latter communication can be via a direct contact between the cells or tissue and the electronic element. Additionally or alternatively, the scaffold element or a portion  
25 thereof may be made conductive in which case at least some electrical signals can be transferred between the electronic element and cells or tissues associated with the scaffold element via electrical current flowing in the scaffold element.

In some embodiments, the electronic element serves for activating or  
deactivating certain functions possessed by the scaffold element, in which case the  
30 scaffold element is made electro-responsive. In these embodiments, the electronic element may or may not communicate with cells or tissue associated with the scaffold element.

Combination of the above embodiments is also contemplated in some embodiments. Thus, the present embodiments contemplate a device in which the electronic element serves both for establishing communication between the electronic circuit and cells and/or tissue associated with the scaffold element, and for activating or deactivating certain functions possessed by the scaffold element. In these embodiments, the scaffold element is both electro-responsive and serves for establishing communication between the cells or tissue associated with the scaffold element and the electronic element.

Representative examples of uses of the electronic element of the present embodiments, include, without limitation, (i) recording and/or monitoring a function and/or activity of a tissue, such as, but not limited to, cardiac tissue, for example, by characterizing propagation (e.g., propagation path, propagation speed, propagation velocity); (ii) stimulation of a tissue (e.g., an engineered tissue); (iii) releasing a therapeutically active agent (e.g., drugs and/or biomolecules) into a biological microenvironment (e.g., tissue, an engineered tissue), e.g., for improving tissue performance; (iv) on-line screening of therapeutically active agents (e.g., for determining agent's toxicity and/or efficacy).

Some embodiments of the present invention provide therapy for an infarcted heart, and/or on-line monitoring and pacing of the heart. Furthermore the scaffold device of the present embodiments may be used for on-line screening of cardiotoxicity of drugs and for basic science experiments in cardiology.

Some exemplary embodiments of the invention pertain to a self-supporting flexible electronic element composed of a SU-8-based polymeric layer and a core made of gold, which can be integrated within a scaffold for tissue engineering. The scaffold device of the present embodiments allows a 3D confluent tissue assembly and allows internal control and monitoring of the tissue or cells forming the tissue.

In experiments performed by the present inventors, an exemplary scaffold device was made up of a mesh of SU-8 (an epoxy photoresist) and gold electrodes delicate enough to contact specific regions of the tissue down to single cell resolution. The electrodes were integrated within 3D polymeric fibrous scaffold elements (e.g., made up of nanofibers, microfibers or being macroporous). Cardiac cells were then seeded into the scaffold elements. After cardiac cell seeding, action potentials were

simultaneously recorded from the scaffold device across multiple electrodes. Signal velocity across the tissue was then calculated based on the recorded action potentials.

In further experiments performed by the present inventors, electro-responsive hydrogels were deposited onto gold electrodes selectively coated with a thin SU-8 layer.

5 Positive and negative electro-responsive hydrogels having oppositely-charged active agents attached thereto via electrostatic interactions, and the release profiles of these agents upon electrical stimulation, were also studied.

Referring now to the drawings, FIG. 28 is a schematic illustration of a scaffold device **280** according to some embodiments of the present invention. Device **280** optionally and preferably comprises a three-dimensional scaffold element **282** and an  
10 electronic element **284** being in contact with scaffold element **282**. FIG. 28 shows element **284** attached to scaffold element **282** from above, but this need not necessarily be the case, since, for some applications, element **284** can be embedded in scaffold element **282** or attached to scaffold element **282** from below.

15 Scaffold element **282** is optionally and preferably made of a polymeric material, as defined and described hereinafter. Representative examples of polymeric material suitable for the present embodiments are provided hereinafter.

An exemplary scaffold device according to some embodiments of the present invention is also presented in FIG. 1B.

20 ***The electronic element:***

Electronic element **284** preferably comprises one or more electrode **286** which can be connected to a measuring device (not shown in FIG. 1) and/or a controller (not shown). For clarity of presentation, FIG. 28 shows a single electrode, but one of ordinary skills in the art, provided with the details described herein would know how to  
25 construct an electronic element with a plurality of electrodes. When element **284** comprises a plurality of electrodes, each electrode is optionally and preferably individually connected to the measuring device and/or controller, so as to form independent communication channels between the scaffold device **280** and the measuring device and/or controller. In some of any of the embodiments described  
30 herein, the electrodes **286** form a mesh, and in some embodiments of the invention the electrodes within the element are parallel to one another.



In some embodiments, the electrode(s) are connected to the polymeric element such that the electrode(s) externally engage cells present at the site at which the device is implanted. In these embodiments, the electrode(s) serves as an extracellular electrode, and the voltage sensitivity of the electrode(s) is preferably selected to allow sensing  
5 extracellular potentials. Typically, the voltage sensitivity of the electrode structures may vary from 1 microvolt to 1 volt.

Generally, each electrode has a conductive core and an electrically-isolating layer.

The conductive core can be made of an electrically-conducting material such as  
10 for example, gold (Au) or any other conductive metals, or any combination thereof, as described herein. Preferably, the core is made of a biocompatible material. An example includes a combination of gold (Au) and chromium (Cr), with gold being 50 weight percents or more, preferably 60, 70, 80 weight percents or more, and even 100 % gold. Other electrically-conducting materials are contemplated, including, but not  
15 limited to, Al, Ti, Ni, Ag, Cr, Pd, Mo, Nb, Cu, Pt, Ag, and Co.

In some embodiments, the conductive core further comprises an additional layer of electrically-conductive material, preferably a biocompatible material. In some embodiments, the additional layer is such that imparts to the electrode, optionally at selected areas, roughness.

The electrically-isolating layer is made of a substance that is non-conductive  
20 under application of voltage. In some embodiments, the electrically-isolating layer is a polymeric layer, made of electrically-insulating polymers, preferably biocompatible such polymers, and optionally and preferably curable polymers, which, upon curing, may provide the electrode(s) with a desired strength or flexibility or elasticity.  
25 Examples include, without limitation, epoxy resins, preferably epoxy photoresists, for example a SU-8 photoresist, polyimides, and silica-based polymers (e.g., PDMS). Other electrically-isolating polymeric materials and materials in general are also contemplated.

A SU-8 photoresist is near UV photoresist based on a SU-8 epoxy resin, as described, for example, in U.S. Patent Nos. 4,237,216 and 4,882,245. Any photoresist  
30 of the SU-8 family is contemplated herein.

Exemplary polyimides usable for forming the polymeric layer include, without limitation, polymers of the family of photosensitive polyimides (PSPI).

A schematic illustration of electrode **286** is shown in FIGs. 29A-B. Electrode **286** has a conductive core **294** and an electrically-isolating layer **288** deposited on core **294** such that a portion **290** of electrode **286** remains partially uncoated in a predetermined of scaffold element **282** location and consequently exposed to an environment **292** surrounding electrode **286**. Environment **292** can be the 3D polymeric material of the scaffold element **282** and/or cells or tissue grown within the 3D polymeric material, or can be a physiological environment, for example, cells or a tissue of an organ which are engaged with an implanted scaffold device.

Core **294** can be made of an electrically-conducting material such as for example, gold (Au) or any other conductive metals, or any combination thereof, as described herein. Layer **288** can be made, for example, from a non-conductive polymeric material. Preferably, layer **288** is a polymeric layer, as described herein. The thickness of layer **288** can range from about 0.1 micron to about 100 microns, or from 1 micron to about 100 microns, or from about 1 micron to about 50 microns, or from about 10 microns to about 30 microns, including any intermediate subranges and values. The thickness of layer **288** is preferably selected to maintain predetermined mechanical properties such as strength, elasticity and flexibility.

Portion **290** can have a dimension of from 1 to 100 microns, preferably from 1 to 50 microns, or from 10 to 50 microns, including any subranges and values therebetween.

In some embodiments of the present invention electrode **286** is exposed to environment **292** at a tip of electrode **286** (FIG. 29A), and in some embodiments of the present invention electrode **286** is exposed to environment **292** at a plurality of discrete locations over electrode **286** (FIG. 29B).

Electrode **286** can be a microelectrode, such that at least one dimension of the electrode ranges from 1 micron to 2000 microns or from 1 micron to 1000 microns. The size of the electrode can be determined according to its intended use, and can be defined by varying parameters of the process of preparing the electrode structure.

Electrode **286** is preferably flexible and can have any shape. In some embodiments, electrode **286** is disposed on, below or within scaffold element **282** along a generally straight line. In some embodiments electrode **286** is disposed on, below or within scaffold element **282** along a curved line, which can be planar or non-planar. Representative examples of shapes of curved lines suitable for the present embodiments

include, without limitation, a wavy line (e.g., a zigzag line, a sinusoidal line, a square wave line, a saw-tooth line), a curvilinear line, a spiral line, a serpentine line, a cycloid, a helical line and any combination thereof.

The advantage of having an electrode shape describing a curved line is that it  
5 allows the electrode to adapt to geometrical changes in the scaffold element. For example, when the scaffold element bends or folds, the curved electrode can stretch so as to conform to the new shape of the scaffold element. The present inventors demonstrated re-shaping electrodes while maintaining a generally constant (e.g., with a tolerance of less than 10% or less than 5% or less than 2%) conductivity as a function of  
10 the strain of the electrode.

***The scaffold element:***

Herein, a scaffold describes a three-dimensional open lattice matrix, typically in a form of a network of microfibers or nanofiber, or in a form of a microporous network.

The scaffold's structure allows entrapment or loading of substances such as  
15 water, small molecules and biomolecules, including cells and tissues.

In some embodiments, the scaffold is a matrix that allows cells to be cultured (i.e., survive and preferably proliferate) thereon and/or therewithin.

A scaffold element as described herein is made of a polymeric material, and is also referred to herein throughout, interchangeably as a three-dimensional polymeric  
20 element.

By "polymeric material" it is meant a single polymer or co-polymer, or two or more of polymers and/or co-polymers. There are no particular limitations to the number or arrangement of polymers used in forming the scaffold as described herein.

The composition of the polymeric material, namely, the polymer or co-polymer  
25 or the ratio of different polymers and/or co-polymers in a mixture of choice, determines mechanical, physical, chemical and biological properties of the scaffold.

For example, the molecular weight and cross-link density of the polymeric material may be selected to control both the mechanical properties of the scaffold and the degradation rate (for degradable scaffolds). The polymeric material of choice  
30 determines the degradability or biodegradability of the scaffold. The electrical properties of the polymeric material determine its performance when subjected to electric stimuli.

A polymeric material composing the scaffold may comprise natural and/or synthetic polymers or co-polymers. In some embodiments, the polymeric material comprises biocompatible polymer and/or co-polymer. In some embodiments, the polymeric material, and the scaffold made therefrom is biodegradable and/or bioerodible, yet non-resorbing or non-biodegradable polymeric materials are also contemplated.

The phrase "non-biodegradable polymer", as used herein, describes a substance which does not undergo degradation under physiological and/or environmental conditions. This term typically refers to substances which decompose under these conditions such that more than 50 percents do not decompose within at least 1 year, preferably within 2 years, 3 years, 4 years, and up to 10 years and even 20 or 50 years.

The terms "non-biodegradable" and "non-resorbing" are equivalent and are used interchangeably herein.

Such non-resorbing polymeric materials may be used to fabricate scaffold structures which are designed for long term or permanent implantation into a host organism.

In exemplary embodiments, non-biodegradable polymeric materials may be biocompatible. Examples of biocompatible non-biodegradable polymeric materials which are useful as scaffold materials include, but are not limited to, polyethylenes, polyvinyl chlorides, polyamides such as nylons, polyesters, rayons, polypropylenes, polyacrylonitriles, acrylics, polyisoprenes, polybutadienes and polybutadiene-polyisoprene copolymers, neoprenes and nitrile rubbers, polyisobutylenes, olefinic rubbers such as ethylene-propylene rubbers, ethylene-propylene-diene monomer rubbers, and polyurethane elastomers, silicone rubbers, fluoroelastomers and fluorosilicone rubbers, homopolymers and copolymers of vinyl acetates such as ethylene vinyl acetate copolymer, homopolymers and copolymers of acrylates such as polymethylmethacrylate, polyethylmethacrylate, polymethacrylate, ethylene glycol dimethacrylate, ethylene dimethacrylate and hydroxymethyl methacrylate, polyvinylpyrrolidones, polyacrylonitrile butadienes, polycarbonates, polyamides, fluoropolymers such as polytetrafluoroethylene and polyvinyl fluoride, polystyrenes, homopolymers and copolymers of styrene acrylonitrile, cellulose acetates, homopolymers and copolymers of acrylonitrile butadiene styrene, polymethylpentenes,

polysulfones, polyesters, polyimides, polyisobutylenes, polymethylstyrenes, and other similar compounds known to those skilled in the art.

In other embodiments, the structural scaffold materials may be a "bioerodible" or "biodegradable" polymer or co-polymer or combinations thereof.

5           The term "biodegradable" as used in the context of the present invention, describes a material which can decompose under physiological and/or environmental conditions into breakdown products. Such physiological and/or environmental conditions include, for example, hydrolysis (decomposition via hydrolytic cleavage), enzymatic catalysis (enzymatic degradation), and mechanical interactions. This term  
10 typically refers to substances that decompose under these conditions such that 50 weight percents of the substance decompose within a time period shorter than one year.

The term "biodegradable" as used in the context of the present invention, also encompasses the term "bioresorbable", which describes a substance that decomposes under physiological conditions to break down to products that undergo bioresorption  
15 into the host-organism, namely, become metabolites of the biochemical systems of the host-organism.

The terms "biodegradable" and "bioerodible" and "bioresorbable" are equivalent and are used interchangeably herein.

Such bioerodible or biodegradable polymeric materials may be used to fabricate  
20 temporary scaffold structures.

In exemplary embodiments, biodegradable or bioerodible structural scaffold materials may be biocompatible. Examples of biocompatible biodegradable polymers which are useful as scaffold materials include, but are not limited to, polylactic acid, polyglycolic acid, polycaprolactone, and copolymers thereof, polyesters such as  
25 polyglycolides, polyanhydrides, polyacrylates, polyalkyl cyanoacrylates such as n-butyl cyanoacrylate and isopropyl cyanoacrylate, polyacrylamides, polyorthoesters, polyphosphazenes, polypeptides, polyurethanes, polystyrenes, polystyrene sulfonic acid, polystyrene carboxylic acid, polyalkylene oxides, alginates, agaroses, dextrans, dextrans, polyanhydrides, biopolymers such as collagens and elastin, alginates,  
30 chitosans, glycosaminoglycans, and co-polymers made of any mixture of such polymers and mixtures of such polymers or co-polymers.

In still other embodiments, a mixture of non-biodegradable and bioerodible and/or biodegradable polymeric materials may be used to form a biomimetic scaffold structure of which part is permanent and part is temporary.

In some embodiments, the scaffold is made of a polymeric material that is  
5 suitable for cell growth and/or for cell adherence. In some embodiments, the scaffold is made of a polymeric material that provides favorable conditions for cells to adhere, proliferate, and organize into a form of a tissue.

Representative examples such polymeric materials include, but are not limited to, polycaprolactone (PCL), gelatin, poly(lactic acid (PLA), poly(glycolic acid) (PGA),  
10 poly(lactic acid-co-glycolic acid) (PLGA), albumin, alginate, decellularized extracellular matrix, as described herein and a variety of other hydrogels, polymers and other materials, and any combination thereof.

In an exemplary embodiment, the polymeric material comprises PCL, gelatin or a combination of PCL and gelatin.

In further exemplary embodiments, the polymeric material comprises naturally  
15 occurring substances, such as, fibrinogen, fibrin, thrombin, chitosan, collagen, alginate, poly(N-isopropylacrylamide), hyaluronate, albumin, collagen, synthetic polyamino acids, prolamines, polysaccharides such as alginate, heparin, and other naturally occurring biodegradable polymers of sugar units.

In an exemplary embodiment, the polymeric material comprises albumin.  
20

In some of these embodiments, the scaffold element is made of or comprises a fibrous polymeric material, and in some embodiments, the fibrous polymeric material comprises nanofibers of the polymer. Fibrous polymeric material can be obtained, for example, by electrospinning, as described in detail hereinunder.

Thus, in some of these embodiments, the scaffold element comprises an  
25 electrospun, or otherwise formed, fibrous polymeric material, for example, an electrospun or otherwise formed, fibrous polycaprolactone (PCL), gelatin, poly(lactic acid (PLA), poly(glycolic acid) (PGA), poly(lactic acid-co-glycolic acid) (PLGA), albumin, and/or alginate.

In further exemplary embodiments, the polymeric material comprises one or  
30 more electro-responsive polymer or co-polymer.

The phrase “electro-responsive polymer”, which is also referred to herein and in the art, interchangeably, as “electroactive polymer”, describes a polymer or co-polymer which undergoes a change in its shape, structure and/or chemical properties in response to electric *stimuli*.

5 In some embodiments, the electro-responsive polymer undergoes a change in its chemical structure such that upon application of voltage, a change in its electronic structure occurs. In some embodiments, the change in the electronic structure is exhibited as a change in the net charge of the polymer, and, in some embodiments, this change is reflected by a change in the net charge of at least some of the functional  
10 groups of the polymer.

Electro-responsive polymers can be, for example, polymers or co-polymers having positively-charged groups (either pendant groups or backbone groups), which, upon potential application, are converted into neutral groups. Exemplary such polymers include, for example, polypyrrole, poly(vinyl amines), poly(vinyl pyridine), and  
15 poly(vinyl imidazole).

Electro-responsive polymers can be, for example, polymers or co-polymers having negatively-charged groups (either pendant groups or backbone groups), which, upon potential application, are converted into neutral groups. Exemplary such polymers include, but are not limited to, ionic polysaccharides, such as alginates or chitosan,  
20 poly(phosphazenes), poly(acrylic acids), and poly(methacrylic acids), and other polymers having negatively-charged groups (either pendant groups or backbone groups) such as carboxylic acid groups, sulfonic acid groups, and halogenated (preferably fluorinated) alcohol groups.

One example is poly(acrylamide-2-methylpropanesulfonic acid) or a co-polymer  
25 comprising same.

By “pendant groups” it is meant herein, and in the art, groups within the side chains of the polymer’s backbone units. For example, a pyridine group is a poly(vinylpyridine) is a positively charged pendant group.

By “backbone groups” it is meant herein, and in the art, groups within the  
30 polymer’s backbone units, which form the polymeric backbone. For example, the nitrogen atom of a pyrrole backbone unit of a polypyrrole is a positively-charged backbone group.

By “positively-charged” and “negatively-charged”, it is meant a net charge in a physiological environment, for example, an aqueous solution at pH of about 7.

In some embodiments, the three-dimensional polymeric element is in a form of a hydrogel. The hydrogel may be a lyophilized or otherwise dried hydrogel.

5 In some embodiments, the hydrogel is made of an electro-responsive polymer, as described herein. Electro-responsive polymers can be prepared, for example, by chemical polymerization (e.g., radical polymerization) or by electropolymerization.

According to still another embodiment, the scaffold is generated from decellularized tissue and more specifically from decellularized extracellular matrix  
10 (ECM) of a tissue.

As used herein the phrase “decellularized ECM of a tissue” refers to the extracellular matrix which supports tissue organization (e.g., a natural tissue) and underwent a decellularization process (*i.e.*, a removal of all cells from the tissue) and is thus completely devoid of any cellular components.

15 The phrase “completely devoid of any cellular components” as used herein refers to being more than 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 %, (e.g., 100 %) devoid of the cellular components present in the natural (e.g., native) tissue. As used herein, the phrase “cellular components” refers to cell membrane components or intracellular components which make up the cell. Examples  
20 of cell components include cell structures (e.g., organelles) or molecules comprised in same. Examples of such include, but are not limited to, cell nuclei, nucleic acids, residual nucleic acids (e.g., fragmented nucleic acid sequences), cell membranes and/or residual cell membranes (e.g., fragmented membranes) which are present in cells of the tissue. It will be appreciated that due to the removal of all cellular components from the  
25 tissue, such a decellularized matrix cannot induce an immunological response when implanted in a subject.

The phrase “extracellular matrix (ECM)” as used herein, refers to a complex network of materials produced and secreted by the cells of the tissue into the surrounding extracellular space and/or medium and which typically together with the  
30 cells of the tissue impart the tissue its mechanical and structural properties. Generally, the ECM includes fibrous elements (particularly collagen, elastin, or reticulin), cell



adhesion polypeptides (e.g., fibronectin, laminin and adhesive glycoproteins), and space-filling molecules [usually glycosaminoglycans (GAG), proteoglycans].

A tissue-of-interest (e.g., pancreas, myocardium, omentum) may be derived from an autologous or non-autologous tissue (e.g., allogeneic or even xenogeneic tissue, 5 due to non-immunogenicity of the resultant decellularized matrix). The tissue is removed from the subject [e.g., an animal, preferably a mammal, such as a pig, monkey or chimpanzee, or alternatively, a deceased human being (shortly after death)] and can be washed e.g. in a sterile saline solution (0.9 % NaCl, pH = 7.4) or phosphate buffered saline (PBS), which can be supplemented with antibiotics such as 10 Penicillin/Streptomycin 250 units/ml. Although whole tissues can be used, for several applications segments of tissues may be cut e.g. sliced. Such tissue segments can be of various dimensions, depending on the original tissue used and the desired application.

Methods of decellularizing tissue are known in the art. See, for example, U.S. Patent Application Publication Nos. 20120156250, 20050013870 and 201000267143, 15 PCT Application Publication Nos. WO 2014/037942 and WO 2009/085547, and U.S. Patent Application No. 61/838,428.

Typically, the scaffold elements of the present embodiments feature a porous structure. The porosity of the scaffold may be controlled by a variety of techniques known to those skilled in the art. The minimum pore size and degree of porosity is 20 dictated, for example, by the need to provide enough room for the cells and for nutrients to filter through the scaffold to the cells, or by the need to releasably incorporate therapeutically active agents, as described hereinafter.

The maximum pore size and porosity is limited by the ability of the scaffold to maintain its mechanical stability. As the porosity is increased, use of polymers having a 25 higher modulus, addition of stiffer polymers as a co-polymer or mixture, or an increase in the cross-link density of the polymer may all be used to increase the stability of the scaffold.

The scaffold elements described herein may be made by any of a variety of techniques known to those skilled in the art. Salt-leaching, porogens, solid-liquid phase 30 separation (sometimes termed freeze-drying or lyophilization), and phase inversion fabrication may all be used to produce porous scaffolds. Fiber pulling and weaving (see, e.g. Vacanti, et al., (1988) Journal of Pediatric Surgery, 23: 3-9) may be used to

produce scaffolds having more aligned polymer threads. Those skilled in the art will recognize that standard polymer processing techniques may be exploited to create polymer scaffolds having a variety of porosities and microstructures.

The scaffold element can be generated separately and then be constructed so as  
5 to be in contact with the electronic element, or be fabricated directly in the presence of the electronic element.

According to a particular embodiment, the scaffold is made by electrospinning the polymeric material, that is, it comprises an electrospun polymeric material.

In some of these embodiments, the electrospinning is performed in the presence  
10 of the electronic component, as is exemplified in the Examples section the follows.

As used herein, the term "electrospinning" refers to a technology which produces electrospun fibers (e.g. nanofibers) from a polymer solution. During this process, one or more polymers of the polymeric material as described herein are liquefied (i.e. melted or dissolved) and placed in a dispenser. An electrostatic field is  
15 employed to generate a positively charged jet from the dispenser to the collector. Thus, a dispenser (e.g., a syringe with metallic needle) is typically connected to a source of high voltage, preferably of positive polarity, while the collector is grounded, thus forming an electrostatic field between the dispenser and the collector. Alternatively, the dispenser can be grounded while the collector is connected to a source of high voltage,  
20 preferably with negative polarity. As will be appreciated by one ordinarily skilled in the art, any of the above configurations establishes motion of positively charged jet from the dispenser to the collector. Reverse polarity for establishing motions of a negatively charged jet from the dispenser to the collector is also contemplated. At the critical voltage, the charge repulsion begins to overcome the surface tension of the liquid drop.  
25 The charged jets depart from the dispenser and travel within the electrostatic field towards the collector. Moving with high velocity in the inter-electrode space, the jet stretches and the solvent therein evaporates, thus forming fibers which are collected on the collector forming the electrospun scaffold.

Several parameters may affect the diameter of the fiber, these include, the size of  
30 the dispensing hole of the dispenser, the dispensing rate, the strength of the electrostatic field, the distance between the dispenser and/or the concentration of the polymeric material used for fabricating the electrospun fiber.

According to some embodiments, the average fiber diameter is between 20 nm - 10 $\mu$ m, 20 nm - 1 $\mu$ m, 100-300 nm, e.g. about 250 nm.

The dispenser can be, for example, a syringe with a metal needle or a bath provided with one or more capillary apertures from which the liquefied polymeric material as described herein can be extruded, e.g., under the action of hydrostatic pressure, mechanical pressure, air pressure and high voltage.

According to one embodiment, the collector is a rotating collector which serves for collecting the electrospun scaffold thereupon. Employing a rotating collector can result in an electrospun scaffold with a continuous gradient of porosity. Such a porosity gradient can be achieved by continuous variation in the velocity of the collector or by a longitudinal motion of the dispenser, these result in a substantial variation in the density and/or spatial distribution of the fibers on the collector and thus, result in a porosity gradient along the radial direction or along the longitudinal direction of the collector, respectively. Typically, but not obligatorily, the rotating collector has a cylindrical shape (e.g., a drum), however, it will be appreciated that the rotating collector can be also of a planar geometry.

According to another embodiment, the collector is a flat ground collector which serves for collecting the electrospun scaffold thereupon. Employing a flat ground collector enables collection of random nanofibers. It will be appreciated that the flat ground collector is typically a horizontal collector or a vertical collector.

According to another exemplary embodiment, adhesive agents are included in the scaffolds (e.g. electrospun fibrous polymeric material) of some of the present embodiments. Such adhesive agents may be used to unite or bond the electrospun polymers together.

Such an adhesive agent may include, without being limited to, gelatin, fibrin, fibronectin, collagen or RGD. Ratios of adhesive agents (e.g. gelatin): polymer may be about 50:50, may be about 40:60, may be about 30:70, may be about 20:80, or may be about 10:90.

According to a particular embodiment, the scaffold comprises spring-like fibers (i.e. coiled fibers), that are also able to stretch with extensibility over 200%, and recoil back to the same position. Such fibers can be generated by electrospinning by fixing the rate of delivery of the polymer solution through the capillary. Thus, for example,

the present inventors have shown that spring-like fibers can be generated if a polymer solution of PCL (e.g. at concentrations between 10% to 17.5% w/v%) dissolved in dichloromethane(DCM) and dimethylformamide (DMF) (for examples in ratios of 3:1, 2:1, 1:1 and 1:2) through a capillary at a rate of 0.1-20 ml/h (e.g. 0.5ml/h).

5 Spring-like fibers can also be generated using PLGA.

Table 1 below presents exemplary compositions which are usable for forming electrospun polymeric material as a scaffold element as described herein.

28  
Table 1

<b>Materials</b>	<b>Solvent</b>
<b>Natural polymers</b>	
Chitosan	90% Acetic acid
Gelatin	Formic acid
Gelatin	TFE
Collagen Type I, II, and III	HFIP
Collagen Type I, II, and III	HFIP
Collagen Type I, II, and III	HFIP
Elastin	HFIP
Hyaluronic acid	DMF/water
Cellulose	NMMO/water
Silk fibroin	Methanol
Phospholipids (Lecithin)	Chloroform/DMF
Fibrinogen	HFIP/10 x minimal essential medium
Hemoglobin	TFE
Fibrous calf thymus Na-DNA	Water/ethanol
Virus M13 viruses	THF
<b>Synthetic polymers</b>	
PLGA	TFE/DMF
PLA	HFIP
PLA	DCM
PLA	DCM/DMF
PLA	DCM/pyridine
PCL	DCM/methanol
PHBV	Chloroform/DMF
PDO	HFIP
PGA	HFIP
PLCL	Acetone
PLCL	DCM
PLLA-DLA	Chloroform
PEUU	HFIP
Cellulose acetate	Acetic acid/water
PEG- <i>b</i> -PLA	Chloroform
EVOH	70% propan-2-ol/water
PVA	Water
PEO	Water
PVP	Ethanol/water
<b>Blended</b>	
PLA/PCL	Chloroform
Gelatin/PVA	Formic acid
PCL/collagen	HFIP
Sodium alginate/PEO	Water

**Blended (cont.)**

Chitosan/PEO	Acetic acid/DMSO
Chitosan/PVA	Acetic acid
Gelatin/elastin/PLGA	HFIP
Silk/PEO	Water
Silk fibroin/chitosan	Formic acid
PDO/elastin	HFIP
PHBV/collagen	HFIP
Hyaluronic acid/gelatin	DMF/water
Collagen/chondroitin sulfate	TFE/water
Collagen/chitosan	HFIP/TFA

**Composites**

PDLA/HA	Chloroform
PCL/CaCO <sub>3</sub>	Chloroform/methanol
PCL/CaCO <sub>3</sub>	DCM/DMF
PCL/HA	DCM/DMF
PLLA/HA	Chloroform
Gelatin/HA	HFIP
PCL/collagen/HA	HFIP
Collagen/HA	HFIP
Gelatin/siloxane	Acetic acid/ethyl acetate/water
PLLA/MWNTs/HA	1, 4-dioxane/DCM
PLGA/HA	DCM/water

**Table 1 (Cont.)**

Alternatively or additionally, the scaffold element as described herein is made of  
 5 a polymeric material as described herein, which forms a hydrogel in contact with the  
 electronic component as described herein.

In some of these embodiments, a hydrogel is formed directly in the presence of  
 an electronic element as described herein. In exemplary embodiments, a hydrogel is  
 made of an electropolymerizable monomer, which undergoes electropolymerization in  
 10 the presence of the electronic element, which serves as the working electrode in the  
 electropolymerization process.

In some of these embodiments, the hydrogel is formed separately, optionally  
 dried, and thereafter the electronic element is integrated therewith.

According to some exemplary embodiments of the present invention, a  
 15 combination of two or more of a hydrogel, a fibrous electrospun polymeric material and  
 a decellularized matrix are used for forming the scaffold element as described herein.

In some embodiments, the scaffold element comprises a hydrogel (e.g., dried hydrogel) made of an electro-responsive polymer and a fibrous polymeric material (e.g., electrospun polymeric material). In some of these embodiments, the fibrous polymeric material is deposited into the hydrogel.

5           The scaffolding can be varied by using a variety of different biopolymers, synthetic polymers, decellularized tissue scaffolds, macroporous scaffolds and more. These in turn, can also be altered to possess unique properties such as drug loading, different mechanical or electrical properties, and all the techniques used for tissue engineering.

10           ***Agents incorporated in or on the scaffold element:***

          According to some of any of the embodiments of the present invention the device further comprises cells incorporated in the 3D polymeric element. Optionally and preferably, the cells form a tissue, such that the device represents an artificial tissue, also referred to herein as a cyborg tissue, or an engineered tissue.

15           In some of these embodiments, the scaffold element comprises 3D polymeric element comprised of a polymeric material that favors tissue formation, as described herein.

          The cells can be, for example, endocardial cells, cardiac adrenergic cells, cardiac fibroblasts, vascular endothelial cells, smooth muscle cells, cardiac progenitor cells,  
20   adult stem cells, embryonic stem cells, mesenchymal stem cells, and any combination thereof.

          The cells can be mammalian cells, including neonatal cells, adult or aged cells, progenitor cells (e.g., derived from a tissue selected from the group consisting of bone marrow, fat and umbilical cord), adult stem cells, embryonic stem cells, mesenchymal  
25   stem cells, genetically transformed cells and/or human cells.

          Exemplary mammalian cells include but are not limited to cardiomyocytes, endocardial cells, cardiac adrenergic cells, cardiac fibroblasts, vascular endothelial cells, smooth muscle cells, cardiac progenitor cells, adult stem cells, embryonic stem cells, mesenchymal stem cells, and any combination thereof.

30           Any other cells are also contemplated.

          The present embodiments envisage seeding any cells onto and/or within the scaffold. Preferably, the cells are viable and remain viable following the seeding. The

cells may comprise a heterogeneous population of cells or alternatively the cells may comprise a homogeneous population of cells. Such cells can be for example, stem cells (such as embryonic stem cells, bone marrow stem cells, cord blood cells, mesenchymal stem cells, adult tissue stem cells), progenitor cells (e.g. progenitor bone cells), or differentiated cells such as chondrocytes, osteoblasts, connective tissue cells (e.g., fibrocytes, fibroblasts and adipose cells), endothelial and epithelial cells. Furthermore, the cells may be of autologous origin or non-autologous origin, such as postpartum-derived cells (as described in U.S. Application Nos. 10/887,012 and 10/887,446). Typically the cells are selected according to the tissue being generated.

According to a particular embodiment, the cells comprise electrically excitable cells such as cardiac cell (e.g. cardiomyocyte), glandular cells and nerve cells (neurons).

As used herein, the term "cardiomyocytes" refers to fully or at least partially differentiated cardiomyocytes. Thus, cardiomyocytes may be derived from stem cells (such as embryonic stem cells or adult stem cells, such as mesenchymal stem cells).

Methods of differentiating stem cells along a cardiac lineage are well known in the art [See, for example, Muller-Ehmsen J, et al., *Circulation*. 2002;105:1720-6; Zhang M, et al., *J Mol Cell Cardiol*. 2001;33:907-21, Xu et al, *Circ Res*. 2002;91:501-508, and U.S. Pat. Appl. No. 20050037489, the contents of which are incorporated by reference herein]. According to one embodiment the stem cells are derived from human stem cell lines, such as H9.2 (Amit, M. et al., 2000. *Dev Biol*. 227:271).

Screening of partially differentiated cardiomyocytes may be performed by a method enabling detection of at least one characteristic associated with a cardiac phenotype, as described hereinbelow, for example via detection of cardiac specific mechanical contraction, detection of cardiac specific structures, detection of cardiac specific proteins, detection of cardiac specific RNAs, detection of cardiac specific electrical activity, and detection of cardiac specific changes in the intracellular concentration of a physiological ion.

Additional cells that may be seeded together with cardiomyocytes include for example endothelial cells and/or fibroblast cells (which may or may not be derived from cardiac tissue). Accordingly, a pool of cardiomyocytes, endothelial cells and fibroblasts (in the presence or absence of an appropriate gel, as described herein below) may be generated and seeded onto the scaffold.



Seeding of the cells on the scaffold element is an important step in the establishment of an engineered tissue. Since it has been observed that the initial distribution of cells within the scaffold after seeding is related to the cell densities subsequently achieved, methods of cell seeding require careful consideration. Thus, 5 cells can be seeded in a scaffold by static loading, or by seeding in stirred flask bioreactors (scaffold is typically suspended from a solid support), in a rotating wall vessel, or using direct perfusion of the cells in medium in a bioreactor. Highest cell density throughout the scaffold is achieved by the latter (direct perfusion) technique.

The cells may be seeded directly onto the scaffold, or alternatively, the cells may 10 be mixed with a gel which is then absorbed onto the interior and exterior surfaces of the scaffold and which may fill some of the pores of the scaffold. Capillary forces will retain the gel on the scaffold before hardening, or the gel may be allowed to harden on the scaffold to become more self-supporting. Alternatively, the cells may be combined with a cell support substrate in the form of a gel optionally including extracellular 15 matrix components. An exemplary gel is Matrigel<sup>TM</sup>, from Becton-Dickinson. Alternatively, the gel may be growth-factor reduced Matrigel, produced by removing most of the growth factors from the gel (see Taub, et al., Proc. Natl. Acad. Sci. USA (1990); 87 (10:4002-6). In another embodiment, the gel may be a collagen I gel, alginate, or agar. Such a gel may also include other extracellular matrix components, 20 such as glycosaminoglycans, fibrin, fibronectin, proteoglycans, and glycoproteins. The gel may also include basement membrane components such as collagen IV and laminin. Enzymes such as proteinases and collagenases may be added to the gel, as may cell response modifiers such as growth factors and chemotactic agents.

Following seeding, the scaffold element-supported cells may be cultured under 25 conditions which allow the formation of 3D structures. According to one embodiment, the scaffold element or the device comprising same is cultured under conditions which allow tissue formation.

The scaffold element-supported cells may be cultured for 1 day, two days, three days, four days, five days, six days, at least 1 week, 10 days or two weeks, three weeks, 30 four weeks.

Additional agents may be incorporated into or on the scaffold of the present embodiments, along with the cells or tissue formed therefrom. Such agents include, but

are not limited to those that promote cell adhesion (e.g. fibronectin, integrins), cell colonization, cell proliferation, cell differentiation, cell extravasation and/or cell migration. Thus, for example, the agent may be an amino acid, a small molecule chemical, a peptide, a polypeptide, a protein, a DNA, an RNA, a lipid and/or a proteoglycan.

According to another embodiment an antibody is incorporated on to the scaffold of the present invention. Preferably the antibody recognizes a cell-surface marker or a cell-secreted agent.

Proteins that may be incorporated into, or on the surface of the scaffolds of the present invention include, but are not limited to extracellular matrix proteins, cell adhesion proteins, growth factors, cytokines, hormones, proteases and protease substrates. Thus, exemplary proteins include vascular endothelial-derived growth factor (VEGF), activin-A, retinoic acid, epidermal growth factor, bone morphogenetic protein, TGF $\beta$ , hepatocyte growth factor, platelet-derived growth factor (PDGF), TGF $\alpha$ , IGF-I and II, hematopoietic growth factors, heparin binding growth factor, peptide growth factors, erythropoietin, interleukins, tumor necrosis factors, interferons, colony stimulating factors, basic and acidic fibroblast growth factors, nerve growth factor (NGF) or muscle morphogenic factor (MMP). The particular growth factor employed should be appropriate to the desired cell activity. The regulatory effects of a large family of growth factors are well known to those skilled in the art.

According to some embodiments of the present invention, the scaffold device further comprises a therapeutically active agent incorporated on or within the 3D polymeric element. According to some embodiments of the present invention, the scaffold device further comprises both cells and/or tissue and a therapeutically active agent.

The therapeutically active agent can be a biomolecule (e.g., a hormone, a factor, a growth factor, an antibody, a peptide, a protein, etc.), a drug, or any other agent that may improve tissue performance.

In some embodiments, the scaffold element comprises both a therapeutically active agent and cells and/or tissue formed therefrom.

According to some of any of the embodiments of the present invention the device comprises a therapeutically active agent in a releasable form, and the electrode structure

is exposed to the therapeutically active agent, such that the therapeutically active agent is released upon transmission of stimulation signals through the electrode.

In some embodiments, the therapeutically active agent is associated, physically (e.g., by absorption or entrapment) or chemically (by e.g., electrostatic interactions),  
5 with the polymeric element, and the electrode structure is exposed to the polymeric material composing the polymeric element, such that the therapeutically active agent is released upon transmission of stimulation signals through the electrode to the polymeric material.

In some of such embodiments, the polymeric element comprises an electro-  
10 responsive polymeric material, as described herein, through which electric signal can be transmitted, and from which the therapeutically active agent can be released upon electric *stimuli* through the electrode in the electronic element. This enables delivering specific cues for tissue development or tissue control in order to improve function or performance of the tissue.

The use of electro-responsive hydrogel or polymer may provide controlled  
15 release of therapeutically active agent into the environment, providing spatially and temporally controlled cues to the tissue as well as providing needed aid to the tissue in event of distress. The environment can be, for example, the cellular microenvironment within the polymeric element, in case cells and/or tissue are comprised therein; and/or  
20 cells or tissue of a bodily organ that are engaged with the scaffold device.

The electro-responsive polymeric material is selected to bind a therapeutically agent by electrostatic interactions. Upon application of a suitable voltage (potential), the net charge of the polymeric material is altered, the electrostatic interactions are interrupted, and as a result, the therapeutically active agent is released to the  
25 environment (e.g., the cellular microenvironment).

In exemplary embodiments, the electro-responsive polymer is a positively charged polymer, as described herein, and the therapeutically active agent is a negatively charged agent.

Exemplary such agents include, for example, non-steroidal anti-inflammatory  
30 agents such as, but not limited to, salicylates, such as aspirin, Sulfosalicylic acid (SSA), disalcid, benorylate, trilisate, safapryn, solprin, diflunisal, and fendosal; acetic acid derivatives, such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin, isoxepac,

furofenac, tiopinac, zidometacin, acematacin, fentiazac, zomepirac, clindanac, oxepinac, felbinac, and ketorolac; fenamates, such as mefenamic, meclofenamic, flufenamic, niflumic, and tolfenamic acids; propionic acid derivatives, such as ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, indoprofen, pirprofen, 5 carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, and tiaprofenic; steroidal anti-inflammatory agents alpha-methyl dexamethasone, dexamethasone-phosphate, beclomethasone dipropionates, clobetasol valerate, desoxymethasone, desoxycorticosterone acetate, dexamethasone, dichlorisone, diflorasone diacetate, diflucortolone valerate, fluadrenolone, fluclorolone acetone, 10 flumethasone pivalate, fluosinolone acetone, flucortine butylesters, fluocortolone, fluprednidene (fluprednylidene) acetate, flurandrenolone, hydrocortisone acetate, hydrocortisone butyrate, difluorosone diacetate, fluradrenolone, difluorosone diacetate, fluradrenolone acetone, betamethasone and the balance of its esters, chlorprednisone, chlorprednisone acetate, hydrocortisone valerate, hydrocortisone cyclopentylpropionate, 15 hydrocortamate, and beclomethasone dipropionate, triamcinolone; ATP, negatively-charged proteins, and Metamizole.

In other exemplary embodiments, the electro-responsive polymer is a negatively charged polymer, as described herein, and the therapeutically active agent is a positively charged agent.

20 Exemplary such agents include, for example, dopamine, norepinephrine, endorphonium, serotonin and other catecholamines, positively charged proteins, positively charged growth factors, and more. Any other positively-charged and negatively-charged small molecule and/or biomolecule (e.g., protein, peptides, nucleic acids, oligonucleotides) therapeutically active agents are contemplated.

25 In some embodiments, the therapeutically active agent is selected suitable for treating or repairing a damaged tissue or a condition associated with a damaged tissue, such as, but not limited to, an infarcted myocardial tissue, as is further detailed hereinbelow.

***Applications:***

30 Any one of the devices described herein is usable for being implanted in, or on, or as a replacement of, a tissue or an organ, or part thereof, of a subject in need thereof.

A device as described herein is therefore an implantable device according to some embodiments of the present invention.

In some of any of the embodiments described herein, the tissue or organ is one that contains electrically excitable cells and is subject to electrical stimulation *in vivo*.

5           The tissue can be, for example, cardiac muscle tissue, striated skeletal muscle tissue, smooth muscle tissue, bone, vasculature, or nerve tissue. Any other tissues or organs are contemplated, for example, liver or kidney. When the device is seeded with cells, the cells are preferably selected in accordance with the tissue or organ intended for implantation of the device therein or thereon.

10           Any one of the devices described herein is also usable for monitoring and/or stimulating an activity and/or a function of a cell. The cell can be a single cell, a plurality of cells or a tissue.

In some embodiments, the activity and/or function is an electrical activity or response to electric *stimuli*.

15           The cell or tissue can be such that is incorporated in the scaffold element of the device. A tissue can be formed by cultivating cell seeded in the scaffold element under suitable conditions.

Any one of the devices described herein is usable for monitoring and/or stimulating an activity and/or a function of the cell or the tissue incorporated in the device *in vivo*, upon implanting the device on or in or in replacement of a tissue or organ, or a part thereof, of a subject. This may be effected by receiving signals transmitted through the electrode, for monitoring the condition of the implanted device; or by transmitting signals through the electrode to the implanted device for stimulating an activity or function of the cell or tissue.

25           Thus, a method of monitoring or controlling a condition or function of an implanted tissue or cell is provided, which comprises implanting a scaffold device as described herein (which incorporates cells or tissue) and recording or transmitting signals (through one or more external electronic device(s)) to an incorporated cell or tissue through the electrode structure.

30           The advantage of using the scaffold device of the present embodiments for monitoring or controlling a condition or function of an implanted tissue or cell is that the same device can serve both for growing the tissue or cell prior to its implantation and for

monitoring or controlling the condition or function of the tissue or cell, once implanted. Since the tissue or cell is grown in the presence of the electronic element, electrical communications of the tissue or cell as well as the polymeric element with the electrode(s) of the electronic element are readily established. Such electrical  
5 communications facilitate monitoring the condition or function of the tissue or cell via electrical signals received, directly or indirectly, from the tissue or cell, and also facilitate controlling the condition or function by electrically stimulating the tissue or cell, or by electrically inducing controlled release of agents from the polymeric element.

In embodiments in which the scaffold device comprises a plurality of electrodes,  
10 the distribution of electrodes can be used for characterizing a propagation (e.g., propagation path, propagation speed, propagation velocity) of a signal across the tissue, and/or for executing synchronized stimulation of the tissue at a plurality of different locations over the tissue. If desired, the plurality of electrodes can also be used for releasing an agent from the polymeric element from a plurality of location in a  
15 synchronized manner.

Any one of the devices described herein, which incorporates a therapeutically active agent, is usable for controlling a release of the therapeutically active agent from the polymeric element in the device, particularly in cases of a polymeric element which comprises an electro-responsive polymeric material.

20 This may be effected by transmitting a stimulating signal through the electrode of the device.

Thus, a method is provided for controllably releasing a therapeutically active agent as described herein to an implanted cell or tissue, which comprises implanting a device as described herein (which incorporates cells or tissue and the therapeutically  
25 active agent as described herein) and transmitting signals (through one or more external electronic device(s)) to an electro-responsive polymeric material composing the polymeric element through the electrode structure. Any one of the devices described herein, which incorporates a therapeutically active agent, is also usable for determining a performance (e.g., toxicity and/or efficacy) of a therapeutically active agent to a cell or  
30 tissue.

In some embodiments, determining a performance (e.g., toxicity and/or efficacy) of a therapeutically active agent to a cell or tissue may be effected by:

utilizing a device comprising a therapeutically active agent as described herein, and a cell or a tissue, both incorporated in the polymeric element, as described herein, preferably a polymeric element made of an electro-responsive polymer as described herein;

5 monitoring a function or activity of a cell or a tissue incorporated in the polymeric element (e.g., by recording electric signals transmitted by the electrode in the device); and

comparing the monitored function or activity of the cell or the tissue with a monitored function or activity of the cell or the tissue without a therapeutically active agent, thereby determining a toxicity and/or efficacy of the therapeutically active agent to the cell or the tissue.

Determining can be effected *in vitro* or *in vivo*, in case the device is implanted in the subject.

Using this methodology, screening therapeutically active agents for toxicity or efficacy for a certain type of tissue or cells can be performed.

In some embodiments, such screening can be by preparing a series of scaffold devices, each incorporating in the polymeric element cells and/or tissues of a certain type, and each independently incorporating a different therapeutically active agent. A toxicity and/or efficacy of the therapeutically active agent to the cells or the tissue, upon electrical stimuli is then determined, and those agents which exhibits efficacy and do not exhibit toxicity are defined as lead candidates for, for example, repairing a function or activity of the cell or tissue, or promoting a function or activity of the cell or tissue.

In some embodiments, the function or activity is an electrophysiological function or activity.

25 The scaffold devices described herein (either alone or seeded with cells) may be used for modifying the electrophysiological function of excitable tissues. Thus, a scaffold device according to the present embodiments can be utilized to restore, enhance or suppress electrophysiological function across a tissue region thereby treating diseases caused by dysfunction in, or damage to, excitable tissues.

30 As used herein the term "treating" refers to inhibiting or arresting the development of a disease, disorder or condition and/or causing the reduction, remission, or regression of a disease, disorder or condition in a subject suffering from, being

predisposed to, or diagnosed with, the disease, disorder or condition. Those of skill in the art will be aware of various methodologies and assays which can be used to assess the development of a disease, disorder or condition, and similarly, various methodologies and assays which can be used to assess the reduction, remission or regression of a disease, disorder or condition.

Examples of diseases and conditions which can be treated using the scaffolds of the present invention include, but are not limited to, glucose regulation disorders (e.g., diabetes mellitus), cardiac arrhythmia (e.g., bradycardia, atrial fibrillation) diseases which are treatable by modulating (i.e., increasing or decreasing) the refractory period of a cardiac tissue (e.g., atrial fibrillation, atrial flutter, atrial tachycardia and ventricular tachycardia), diseases which are treatable by modulating (i.e., increasing or decreasing) neural excitability (e.g., epilepsy, Parkinson's disease and Alzheimer's disease) and diseases and conditions which are treatable by modulating (i.e., increasing or decreasing) pyramidal or purkinje cell coupling (e.g., cerebrovascular accident, epilepsy and pain (e.g., phantom pain).

According to a particular embodiment, the disorder is a cardiac disorder which is associated with a defective or absent myocardium.

Thus, according to another aspect of the present invention there is provided a method of treating a cardiac disorder associated with a defective or absent myocardium in a subject, the method comprising transplanting a scaffold device as described herein into the subject.

The method may be applied to repair cardiac tissue in a human subject having a cardiac disorder so as to thereby treat the disorder. The method can also be applied to repair cardiac tissue susceptible to be associated with future onset or development of a cardiac disorder so as to thereby inhibit such onset or development.

The present embodiments can be advantageously used to treat disorders associated with, for example, necrotic, apoptotic, damaged, dysfunctional or morphologically abnormal myocardium. Such disorders include, but are not limited to, ischemic heart disease, cardiac infarction, rheumatic heart disease, endocarditis, autoimmune cardiac disease, valvular heart disease, congenital heart disorders, cardiac rhythm disorders, impaired myocardial conductivity and cardiac insufficiency.



According to one embodiment, the method according to this aspect of the present invention can be advantageously used to efficiently reverse, inhibit or prevent cardiac damage caused by ischemia resulting from myocardial infarction.

5 According to another embodiment, the method according to this aspect of the present invention can be used to treat cardiac disorders characterized by abnormal cardiac rhythm, such as, for example, cardiac arrhythmia.

As used herein the phrase "cardiac arrhythmia" refers to any variation from the normal rhythm of the heart beat, including, but not limited to, sinus arrhythmia, premature heat, heart block, atrial fibrillation, atrial flutter, pulsus alternans and  
10 paroxysmal tachycardia.

According to another embodiment, the method according to this aspect of the present invention can be used to treat impaired cardiac function resulting from tissue loss or dysfunction that occur at critical sites in the electrical conduction system of the heart, that may lead to inefficient rhythm initiation or impulse conduction resulting in  
15 abnormalities in heart rate.

The method according to this aspect of the present invention is effected by transplanting a scaffold device as described herein to the heart of the subject.

As used herein, "transplanting" refers to providing the scaffold of the present invention (with or without cells), using any suitable route. This term is used herein  
20 interchangeably with "implantation" or "implanting".

In some embodiments, implantation of a scaffold device as described herein is performed while using the scaffold device as described herein in a form of a patch, such as, but not limited to, a cardiac patch. For example, a cardiac patch can be provided by growing an engineered cardiac tissue using the polymeric element as a scaffold. The  
25 polymeric element can have a surface configured to be joined to the surface of the host heart such that the engineered cardiac tissue contacts the tissue of the host heart.

Similarly, the scaffold device can be configured to be joined to a surface of other host organs, including, but not limited to, a host liver, a host skin, a host kidney, a host pancreas, etc.

30 The devices, systems and methods or uses described herein can be utilized in a variety of different manners. The device can be fabricated and utilized in many different configurations so as to adapt it to the intended use, whether it be a different

kind of tissue (e.g., cardiac, liver, kidney etc.), a different kind of injury (e.g., different sizes and types of myocardial infarctions, etc.), different kinds of experiments (e.g., drug testing, injury control, release protocols etc.), and different types of monitoring (e.g., action potential, stimulation, factor/drug release).

5           ***The system:***

FIG. 30 is a schematic illustration of a system **300** for controlling, treating and/or extracting information from cells and/or tissue incorporated in a scaffold element of a device, according to some embodiments of the present invention. System **300** comprises scaffold device **280** and one or more electric devices **302**, **304**. For example, device **302**  
10 can be a controller configured to transmit signals through the electrode(s) of scaffold device **280**, and device **304** can be a measuring device configured for receiving signals conveyed via the electrodes of scaffold device **280**. Signals received from the electrode(s) are optionally and preferably digitizing for example, by device **304** or an external analog-to-digital (A2D) circuit **310**. Signals transmitted to the electrodes are  
15 optionally and preferably analog signals. In some embodiments of the present invention device **302** generates digital signals which are thereafter converted into analog signals for example, by device **302** or an external digital-to-analog (D2A) circuit **312**.

Any of devices **302** and **304** can include a power source or they can be connected to an external power source. In some embodiments system **300** comprises device **302**  
20 but not device **304**, in some embodiments system **300** comprises device **304** but not device **302**, and in some embodiments system **300** comprises both device **302** and device **304**. Preferably, each of devices **302** and **304** communicates separately with each of the electrodes of scaffold device **280** thereby allowing transmitting or receiving different signals (and/or different timings) to or from different locations over the scaffold  
25 element. In some embodiments of the present invention a coded interface (not shown) receives different signals from different electrodes and transmits each of at least some of the different signals to the measuring device **304**. A coded interface can also be used for transmitting different signals through different electrode structures. Also contemplated, is the use of a multiplexer, for combining two or more communication channels  
30 originated from the electrodes.

Any of devices **302** and **304** can be provided as a data processor, such as a general purpose computer or dedicated circuitry, configured to transmit and/or receive

signals from the electronic element. When the data processor receives signals from the electronic element, the data processor is preferably supplemented by a computer software product that allows the processor to process the signals and provides data pertaining to the environment in which the exposed part(s) of the electrode structure is present. The data can be displayed on a display device or transmitted to a computer readable medium. The processing can be done immediately after the acquisition of the signals by the electronic element (*e.g.*, within less than 1 hour or within less than 1 minute or within less than 1 second or within a few milliseconds), or it can be done off line. When the processing is done off line, the signals are preferably recorded in a digital or analog form on a storage medium as known in the art.

According to some embodiments of the present invention system **300** comprises an amplifier **306** configured for amplifying signals transmitted through the electrode(s). Optionally and preferably the electrode(s) is connected to the amplifier **306** via a pre-amplifier circuit **308**. Amplifier **306** and/or pre-amplifier **308** can be provided separately from devices **302** and **304** or they can be integral parts thereof. Also contemplated, are embodiments in which amplifier **306** and/or pre-amplifier **308** are integral parts of scaffold device **280**.

FIG. 1 illustrates an operation principle of an exemplary system according to some embodiments of the invention. The system comprises scaffold device **280** as described herein, that combines both a porous substrate allowing continuous and confluent tissue assembly. In the exemplified illustration, the scaffold device incorporates cardiomyocytes cultivation. The electrodes **286** are distributed throughout the scaffold element **282** for stimulating the tissue and/or conveying signals from the tissue and/or for actuating release of an agent (*e.g.*, drug or factor) loaded onto scaffold element **282**. A computer **302/304** may serve both as a controller and as a measuring device, wherein stimulating and/or actuating signals can be transmitted by the computer and information signals from the tissue can be recorded and/or displayed by the computer.

The system of the present embodiments can serve both as a scaffold for (*e.g.*, cardiac) tissue generation and for monitoring and controlling an implanted engineered tissue from outside. The ability to electrically control the tissue allows recording

(monitoring), stimulating and controlling/stimulating drug release from (e.g., electrically responsive) polymers molded onto the electrodes.

***Fabrication:***

A device as described herein can be fabricated by fabricating the electronic  
5 element as desired (for example, as described in the Examples section the follows) and depositing/molding thereon a 3D polymeric element as described herein.

In some embodiments, the formation of the polymeric element is performed in the presence of the electronic element. In exemplary such embodiments, the polymeric element is formed by electrospinning, and the electrospinning is performed in the  
10 presence of the electronic element, such that the electrospun polymeric material is formed on the electronic component. In other exemplary embodiments, the formation of the polymeric element is performed by electropolymerization of an electropolymerizable polymer, while using the electronic element as a working electrode.

In some embodiments, a polymeric element is formed and is then deposited o  
15 molded onto or around the electronic component. In exemplary such embodiments, a hydrogel or a lyophilized hydrogel is deposited in the electronic element by means of, for example, a micromanipulator or blotting from a volatile liquid solution, as exemplified hereinafter.

20 ***General:***

As used herein the term "about" refers to  $\pm 10\%$ .

The terms "comprises", "comprising", "includes", "including", "having" and their conjugates mean "including but not limited to".

The term "consisting of" means "including and limited to".

25 The term "consisting essentially of" means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.

As used herein, the singular form "a", "an" and "the" include plural references  
30 unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof.

Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should  
5 be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies  
10 regardless of the breadth of the range.

Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases “ranging/ranges between” a first indicate number and a second indicate number and “ranging/ranges from” a first indicate number “to” a second indicate number are used herein  
15 interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.

As used herein the term "method" refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known  
20 manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.

It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for  
25 brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.

Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.

5

## EXAMPLES

Reference is now made to the following examples, which together with the above descriptions illustrate some embodiments of the invention in a non limiting fashion.

### *MATERIALS AND METHODS*

10

Electrospinning was performed as described hereinbelow.

A 4" simple silicon wafer was obtained from University wafers.

SU-8 3005 and SU-8 3025 photoresists were obtained from Microchem.

AZ5214E, AZ726 and Propylene glycol monomethyl ether acetate (PGMEA) was obtained from microchemicals.

15

PCL, gelatin, albumin, poly(2-acrylamido-2-methylpropane sulfonic acid-co-n-butylmethacrylate) and polypyrrole, were obtained from Sigma Aldrich (MO,USA).

Other chemicals were obtained as indicated below.

All other chemicals were obtained from known vendors.

20

Rat neonatal ventricular cardiomyocytes were obtained from Harlan, Israel, and were grown growth medium M-199 (Biological Industries).

SEM measurements were performed using JEOL model JSM-840A.

25

Fluorescent microscopy was performed using a fluorescence microscope (Nikon Eclipse TI), and immunostaining. A device incorporating cardiac cells in a fibrous scaffold, prepared as described herein, was treated by fixing and permeabilizing the cells in 100% cold methanol for 10 minutes. The device was thereafter washed three times in DMEM-based buffer and then cells were blocked for 1 hour at room temperature by incubating with DMEM-based buffer containing 2 % FBS, after which the samples were washed three times. The samples were then incubated with primary antibodies to detect  $\alpha$ -sarcomeric actinin (1:750, Sigma-Aldrich), troponin (1:200, Abcam), and vimentin (1:100, Invitrogen, Carlsbad, CA), washed three times and incubated for 1 hour with Alexa Fluor 647 conjugated goat anti-mouse antibody (1:500; Jackson) and Alexa Fluor 488 conjugated goat anti-rabbit antibody (1:500; Jackson). For nuclei detection, the

30

samples were incubated for 3 minutes with Hoechst 33258 (1:100; Sigma) and washed three times.

### **EXAMPLE 1**

#### ***Fabrication of an electronic element***

5 The following presents a general procedure for fabricating an electronic element according to some embodiments of the present invention.

A thin metal sacrificial layer is sputtered, using photolithography and metal evaporation to create nets of photoresist and electrodes, as exemplified in Figure 2. A mask used during photolithography gives the electronic components its shape. The electrodes are exposed only in small pads at one end and to a connector at the other end, as exemplified in Figure 3. The connector is designed so as to fit into a Multi Channel Systems pre-amplifier to allow signal transduction to and from an amplifier and/or to and from a computer.

15 The following describes exemplary procedures for preparing exemplary electronic elements according to some embodiments of the present invention.

A 4" square silicon wafer was cleaned by  $N_2$ , and a 10 nm layer of Ni was deposited thereon by vapor evaporation, forming a sacrificial layer. Then, a 5 micron thick layer of pre-baked SU-8 3005 photoresist, as a polymeric layer, was deposited by spin coating onto the wafer, and was cross-linked by UV exposure through a an in-house made photolithography mask that gives the device its shape. Thereafter, the photoresist was baked again, developed in PGMEA and cured at a high temperature to achieve final strength.

25 Then, a very thin layer of AZ5214E photoresist was deposited by spin coating and baked, cross-linked by UV with a mask that defines the electrodes on the device, baked again and fully exposed to UV for a long time without a mask to reverse the pattern, and then developed in AZ726.

Thereafter, a 5 nm of Cr and 200 nm of Au are evaporated onto the device and the device is allowed to soak in NMP for 24 hours to remove all the Cr and Au from areas where electrodes are not defined. At the end, another 20 microns thick layer of SU-8 3025 photoresist is deposited by spin coating onto the device, baked, cross-linked

by UV with a third mask defining the passivation of the electrodes and then baked, developed in PGMEA and cured in a high temperature.

The whole wafer was then soaked in 21 % nitric acid to allow the bottom Nickel layer to etch and release the device. The device was then washed and dried gently.

5 FIGs. 2A-B present photographs of the released electronic element. The gold electrodes are plainly visible, and are fully passivated throughout their length and only exposed at both edges (tips) to allow contact with the tissue and e.g., a pre-amplifier.

FIG. 3 presents a microscope image of an exposed tip of a gold electrode within an exemplary electronic element. The dimensions of this exemplary exposed tip are  
10 about 30 minrons.

Generally, a dimension of the exposed tip may range from 1 to 100 microns, or from 1 to 50 microns, or from 10 to 50 microns.

## **EXAMPLE 2**

### ***Fabrication of a 3D polymeric element in association with the electronic element***

An electronic element prepared, for example, as described in Example 1, is covered with a polymeric material, as described in any one of the respective embodiments herein to generate a scaffold, e.g., a three dimensional scaffold or three dimensional polymeric element, for promoting cell adhesion and tissue generation, as  
20 exemplified in Figures 4 and 5.

In an exemplary process, a fibrous scaffold is generated by electrospinning. Briefly, electrospinning is performed by injecting a solution of a polymer (such as, but not limited to, protein, synthetic polymer, natural polymer, or any other polymer as described herein in any one of the respective embodiments and any combination  
25 thereof) in a solvent through a needle into a strong (several to 30kV) electric field where one electrode is attached to the needle and the ground is attached to a conducting collector. The strong electric field and repulsion forces of the solvents in the field make the polymer stretch to sizes of up to tens of nanometers and collect on the collector. The device is laid on the collector and the fibers are spun on it from one side and then  
30 the other.



Alternatively, a hydrogel scaffold or other 3D scaffolds are prepared, using methodologies known in the art, such as decellularization of natural matrices, free radical polymerization or electropolymerization.

Then, optionally, cells (e.g., cardiomyocytes) are seeded onto the scaffold and  
5 the scaffold is incubated under suitable conditions to allow tissue generation, as exemplified in Figures 6 and 7. Different cells can be seeded, to provide different types of tissue generation. Exemplary such cells are neurons. Seeding and culture conditions (during incubation) are selected suitable for the selected cells.

The following describes exemplary procedures for further treating the obtained  
10 electronic device by depositing thereon a polymeric material, such as a 3D scaffold.

In one exemplary procedure, a mixture of PCL and Gelatin, which is both strong and promotes cell attachment and tissue generation, was deposited onto the device by a process of electrospinning.

Briefly, 10 % gelatin (Sigma, St. Louis, MO) and 10 % PCL (Sigma, St. Louis,  
15 MO) were separately dissolved in 2,2,2-trifluoroethanol (Acros, Belgium) overnight at room temperature. The next day, the solutions were mixed in the ratio of 1 : 1. Using a syringe pump (Harvard apparatus, Holliston, MA), the polymer solution was delivered through a stainless steel 20G capillary at a feeding rate of 0.5 mL h<sup>-1</sup>. A high voltage power supply (Glassman high voltage inc.) was used to apply a 10 kV potential between  
20 the capillary tip and the collector, positioned 10 cm beneath the tip.

An electronic component produced as described in Example 1 hereinabove (see, for example, Figures 2A-B) was laid on the collector and the fibers were spun on it from one side and then the other.

In another exemplary procedure a scaffold containing albumin was deposited  
25 onto the device by a process of electrospinning.

Bovine serum albumin [BSA; Fraction V, MP Biomedicals, Aurora, OH; 10% and 14% (w/v)] was dissolved in TFE and distilled water (9:1, respectively), following with addition of excess  $\beta$ -mercaptoethanol (Merck, Darmstadt, Germany) for overnight reaction. The solution was electrospun at room temperature, using a syringe pump  
30 (Harvard Apparatus) delivered at a rate of 2 mL/h. A high voltage supply was used to apply a 12 kV potential between the capillary tip and the grounded aluminum collector placed at a distance of 14 cm. Randomly oriented scaffolds were collected on a round

plate of 13 cm in diameter. Aligned scaffolds were collected on a rotating vertical wheel of 20 cm in diameter and 1 cm in thickness. The scaffolds were dried under vacuum, and further kept in a desiccator. Fiber diameter and pore size were measured using ImageJ (NIH).

5 An electronic component produced as described in Example 1 hereinabove (see, for example, Figures 2A-B) was laid on the collector and the fibers were spun on it from one side and then the other. FIG. 4 presents an image of the electronic element shown in Figures 2A and 2B after PCL/Gelatin nanofibers have been electrospun on it to form a scaffold to allow tissue organization.

10 FIG. 5A presents a scanning electron micrograph (SEM) of an electrode structure comprising a gold electrode coated by SU-8, as presented in Figures 2A-B, and covered by PCL/gelatin fibrous scaffold.

FIG. 5B presents a scanning electron micrograph (SEM) of an electrode structure comprising a gold electrode coated by SU-8, as shown in Figures 2A-B, and  
15 covered by albumin fibrous scaffold.

A device thus prepared was then washed to allow removal of all acids and solvents and cell seeding for tissue generation was performed, using rat neonatal ventricular cardiomyocytes. The device was incubated in an appropriate medium and conditions for 3-7 days, for tissue generation. The final device is also referred to herein  
20 as "cyborg tissue".

Cardiac cells were isolated according to Tel Aviv University ethical use protocols as previously described (Dvir et al., 2006 *Tissue Eng* **12**(10):2843–2852.). Briefly, left ventricles of 0–3-day-old neonatal Sprague–Dawley rats were harvested and cells were isolated using six cycles (30 minutes each) of enzyme digestion with  
25 collagenase type II (95 U/mL; Worthington, Lakewood, NJ) and pancreatin (0.6 mg/mL; Sigma–Aldrich) in Dulbecco's modified Eagle Medium (DMEM, CaCl<sub>2</sub>·2H<sub>2</sub>O (1.8 mM), KCl (5.36 mM), MgSO<sub>4</sub>·7H<sub>2</sub>O (0.81 mM), NaCl (0.1 M), NaHCO<sub>3</sub> (0.44 mM), NaH<sub>2</sub>PO<sub>4</sub> (0.9 mM)). After each round of digestion cells were centrifuged (600G, 5 minutes) and re-suspended in culture medium composed of M-199 supplemented with  
30 0.6 mM CuSO<sub>4</sub>·H<sub>2</sub>O, 0.5 mM ZnSO<sub>4</sub>·7H<sub>2</sub>O, 1.5 mM vitamin B12, 500 U/mL Penicillin and 100 mg/mL streptomycin, and 0.5% (v/v) FBS. To enrich the cardiomyocytes population, cells were suspended in culture medium with 5% FBS and

pre-plated twice (30 minutes). Cell number and viability was determined by hemocytometer and trypan blue exclusion assay.

A device covered with electrospun Albumin fibers was seeded with  $10^6$  neonatal rat ventricular myocytes, and the cells were allowed to grow for 4-5 days, in the presence of a M-199 growth medium supplemented with 0.6 mM  $\text{CuSO}_4 \cdot \text{H}_2\text{O}$ , 0.5 mM  $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ , 1.5 mM vitamin B12, 500 U/mL Penicillin and 100 mg/mL streptomycin, and 5% (v/v) FBS.

FIG. 6 presents an image of an electronic element as shown in FIGs. 2A-B covered with PCL/gelatin fibers after it has been seeded with cardiomyocytes, as described hereinabove. The device when free-standing is flexible and retains its electrical properties while being able to serve as a scaffold for tissue generation.

FIG. 7A presents a fluorescent microscope image of rat neonatal ventricular cardiomyocytes seeded on a device as shown in Figure 6. The cells are elongated and show massive actin striation indicative of mature tissue formation and cell-cell and cell-matrix interactions. It is shown that cells grow directly on the gold electrodes. This connection enables the electrodes to sense action potentials generated from the tissue and transmit electrical stimuli to the tissue.

FIG. 7B presents a fluorescent microscope image of rat neonatal ventricular cardiomyocytes seeded on a device having an electrospun albumin as a polymeric element, as shown in Figure 5B.

### **EXAMPLE 3**

#### ***In vivo implantation***

FIG. 9 is a photograph showing subcutaneous implantation of an engineered (cyborg) tissue (a device seeded with cells, upon tissue formation) according to some embodiments of the present invention into a Sprague-Dawly rat.

A Sprague-Dawly rat was anesthetized, a small patch from its back was shaved and then a small incision was made and the device was placed therein subcutaneously, as shown in FIG. 9. The device was placed such that the electrode array is inside the animal while the connector to the amplifier protrudes from the skin. Stitches were made to both sides of the connector and glue was used to strengthen the device's position in the animal and help close up the wound.

After allowing a few days to recover the animal was again anesthetized and the device was connected to the computer through the same system as before. FIG. 10 is a photograph showing recording action potentials and actuating the implanted engineered (cyborg) tissue, upon sedating the animal and connecting it to a pre-amplifier.

5

#### **EXAMPLE 4**

##### ***In vitro assays – Monitoring and Stimulating***

FIG. 8 presents an exemplary system set up for electrical signal readings. The engineered (cyborg) tissue is connected to an adaptor and into a miniature pre-amplifier and then into another filter/amplifier, from there it goes into a main digitizing unit and into a computer for data analysis.

After the device was incubated for a time period that allows tissue generation, the obtained cyborg tissue was connected to the pre-amplifier and monitored through the computer, using a system as exemplified in Figure 8. This allows monitoring the progress of tissue formation as well as studying the influence of different conditions and substances on the tissue, an approach that could replace animal drug testing and make it easier and simpler. In an exemplary assay, a device, as shown for example, in FIG. 5B, having an electrospun albumin fibers as the 3D polymeric element in association with the electronic element as shown in Figures 2A and 2B, was seeded with  $10^6$  neonatal rat ventricular myocytes, and the cells were allowed to grow for 4-5 days, in the presence of a M-199 growth medium supplemented with 0.6 mM  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ , 0.5 mM  $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ , 1.5 mM vitamin B12, 500 U/mL Penicillin and 100 mg/mL streptomycin, and 5% (v/v) FBS.

At the time of the recording, the device was connected to a ME64-FAI-MPA-System by multichannel systems (Germany). Action potentials were recorded using the MC rack software which allows recording over multiple electrodes simultaneously.

After action potentials were recorded, 100 nM of noradrenaline was added to the growth medium and the device was allowed to incubate for 15 minutes after which the device was reconnected and action potentials were again recorded.

FIGs. 11A-B present action potentials recorded from a single (FIG. 11A) and multiple (FIG. 11B) electrodes in the above-described assay. The use of multiple electrodes allows calculating signal velocity and locating problems in specific areas.

30

The action potentials recorded upon subjecting the cyborg tissue to a stimulating drug were also recorded.

FIG. 12 presents action potentials recorded from a single electrode of the device cultured with neonatal rat ventricular cardiomyocytes. The top shows the action potentials before adding a stimulating drug (Noradrenalin) and the bottom shows the action potentials recorded after the addition of the drug. As shown, the frequency of the action potentials has increased due to the response of the tissue to the drug.

Since the electrodes are integrated within the tissue in a variety of different arrays, generating electric pulses and stimulating specific regions in the engineered tissue are enabled. This allows pacing the tissue as well as aiding in tissue formation.

The influence of electrical stimulation from within the device was tested. A device, as shown for example, in FIG. 7B, having an albumin fibrous scaffold in association with the electronic element as shown in Figures 2A and 2B, and cultured with neonatal rat ventricular cardiomyocytes, was incubated with a fluorescent calcium probe that fluoresces when the tissue contracts.

In brief, the device was incubated with 10  $\mu$ M fluo-4 AM (Invitrogen) and 0.1 % Pluronic F-127 for 45 minutes at 37 °C and then washed in Tyrodes solution 3 times. The calcium transients were imaged using Nikon eclipse Ti inverted research microscope. The images were acquired with a Hamamatsu ORCA - flash 4.0 camera at 100 frame/s with 3  $\mu$ m/pixel spatial resolution. Intensity of fluorescence over time was measured using ImageJ software. The cells were stimulated using an STG-4002 stimulus generator from multichannel systems with 50 ms long, 3 volts strong pulses.

Fluorescence was measured throughout ten different points in the cultured tissue.

FIGs. 13A-B present the data obtained. FIG. 13A presents the tissue before stimulation, showing sporadic contractions throughout the tissue and no synchronized contractions. FIG. 13B is after the tissue was stimulated at a 1 Hz pace from within the device. All measured points are synchronized and contract together as can be observed from their convergent peaks.

**EXAMPLE 5*****Drug-releasing devices having Electro-responsive polymers***

In some embodiments of the present invention, the three dimensional polymeric element is formed from an electro-responsive polymer. In these embodiments, a drug  
5 can be in association with the polymeric matrix, through, for example, electrostatic interactions, and be released therefrom upon electric stimulation.

FIG. 14 presents a schematic illustration of such a device. Upon application of electric power, the drug is released from the electro-responsive polymer that is in contact with the electronic element.

10 The following describes exemplary procedures for depositing drug-releasing positive and negative electro-responsive polymers:

***Preparation of a PolyAMPS (negative polymer) hydrogel:***

2-acrylamido-2-methylpropanesulfonic acid (AMPS) and n-butylmethacrylate (BMA) were purchased from Acros (Belgium). Cross linkers N'N'  
15 methylenebisacrylamide (MBMA), initiators Tetra methyl ethylene di-amine (TEMED), Ammonium persulfate (Aps) and Drug model Dopamine & Norepinephrine were purchased from Sigma (St. Louis, Mo, USA). DMF was purchased from Bio lab, Israel and NaOH (Merck, Germany) was used as a solution. All materials were used as received.

20 A series of cross-linked random copolymers poly(AMPS/BMA) was synthesized by using MBMA as a cross linker (0.8, 1.2, 1.6 mole % of the monomers) and a mixture of APS and TEMED (10:1 V/V %) as an initiator (0.05, 0.075, 0.1 mole % of the monomers). The monomers composition ratio AMPS/BMA was a 27/73 mole ratio.

A mixture of monomers, initiator and cross linker was dissolved in DMF (190  
25 mole % of the monomers). Polymerization was performed in PCR's conical tubes at 60 °C for 3 days. After polymerization, the polymers were removed from the test tubes and washed in a water/acetone (50/50 v/v %) solvent mixture to extract unreacted compounds. The solvent was replaced daily for a week. After the hydrogel reached equilibrium, it was dried either by lyophilization, at ambient conditions (atmosphere) or  
30 at hood conditions, as detailed hereinbelow.

Hydrogels loaded with a drug (e.g., dopamine or norepinephrin) were prepared by treating the obtained co-polymer with a NaOH solution, so as to form a sodium salt

of the sulfonic acid groups, and reacting the obtained salt with a saturated solution of the drug.

In brief, after the hydrogel was dried, it was mixed, for three days, in NaOH aqueous solution (2 M) in 15 ml test-tube. This process converts the  $-\text{SO}_3\text{H}$  group to  $-\text{SO}_3\text{Na}$ . Afterwards, a similar process was used by placing the hydrogel in a half-saturated aqueous solution of the drug (0.2 M), which converted the  $-\text{SO}_3\text{Na}$  group to  $-\text{SO}_3\text{D}$  (where D is an indication for the drug group).

The dried hydrogel is deposited in the electronic element by means of a micromanipulator or by immersing the hydrogel in a volatile liquid and then blotting it onto the electronic element. In brief, the gel is cut into very small pieces and dispersed in acetone at a very low concentration. A 0.5 microliter drop is placed on the electrode and is allowed to dry. Microscopy is used to determine if the gel is appropriately located.

Optionally, a layer of electrospun polymeric material (e.g., albumin) is then deposited.

***Preparation of polypyrrole (positive polymer) hydrogel:***

Pyrrole was at room temperature in a 10-mL one-compartment cell, using an electrochemical workstation under computer control. The gold-based microelectrodes, prepared as described in Example 1 hereinabove, were used as working electrodes. The counter electrode was platinum wire and the reference electrode was a saturated calomel electrode (SCE). The electrolyte was an aqueous solution (100 ml) containing 0.2 M pyrrole (1.39 ml) and 0.2 M sulfosalicylic acid (5.08 grams), which was degassed by nitrogen stream before polymerization was effected. The SSA-doped PPy films (PPy-SSA) were prepared on the gold microelectrodes by galvanostatic polymerization using a current density of  $2.5 \text{ mA/cm}^2$  for 800 seconds. The as-prepared PPy-SSA films were rinsed with de-ionized water and dried in air at room temperature. A second layer was thereafter deposited by using an aqueous solution (100 ml) of 0.2 M pyrrole and 0.1 M NaCl (0.5844 grams), subjected to a galvanostatic polymerization with a current density of  $2 \text{ mA/cm}^2$  for 500 seconds.

FIG. 15A presents a SEM image of a bare electronic element as described in Example 1 (top image) and an image obtained by fluorescent microscopy after (bottom image) deposition of PolyAMPS polymer loaded with the fluorescent substance –

Fluorescein. Fluorescein was loaded into the polymeric element by placing the gel in a solution containing the fluorescein.

The release profile of dopamine from device polymeric element made of a positive electro-responsive polymer as described herein was measured as follows:

5 Disc shaped preloaded slices of formed hydrogel (2-3 mm) were placed between two Graphite electrodes (1 cm apart) in a plastic culture plate. The electrodes were connected to a stimulus generator (STG-4002 multichannel systems, Germany), and the plate was filled with a medium of PBS (0.35 ml). A DC pulse of different intensities (0-8 volt) and different durations (0-15 minutes) was supplied.

10 Nano-Drop spectrophotometer (ND-1000 spectrophotometer, Thermo scientific, Wilmington DE U.S.A) at a wave length of 462 was used to examine the light absorbance of the medium. The relation between the light absorbance and the concentration is given by Beer-Lambert as a linear equation:

$$A = \epsilon lc$$

15 wherein A is the light absorbance, l is the length of the light through the sample [m], C is the concentration in [M], and  $\epsilon$  is the molar absorptivity [ $\text{m}^{-1}\text{M}^{-1}$ ].

FIG. 15B presents the release profile of dopamine from a poly(2-acrylamido-2-methylpropane sulfonic acid-co-n-butylmethacrylate) scaffold, as described herein, as measured by optical density. The arrows showing the time points at which voltage was applied to the device. An on-off behavior of the drug release is clearly shown, with a much higher drug release rate when voltage is applied (on) than when it is not applied (off).

25 FIG. 16 presents a scanning electron micrograph (SEM) of a positive electro-responsive polymer, polypyrrole, deposited on a gold electrode with a TiN layer, prepared as described in Example 6 hereinafter.

The release profile of Sulfosalicylic acid (SSA) from the polypyrrole hydrogel scaffold was measured by Nano-Drop spectrophotometer (ND-1000 spectrophotometer, Thermo scientific, Wilmington DE U.S.A), as described hereinabove, at a wave length of 280 nm.

30 FIG. 17 shows the release profile of SSA from a polypyrrole scaffold. The on-off behavior is shown herein too. When voltage is applied the drug is released into the polymer's vicinity and when voltage application is discontinued drug release ceases.



**EXAMPLE 6*****Electrodes having titanium nitride deposited therein***

Titanium Nitride was utilized for improving the quality of the action potentials recorded from the device. Titanium nitride has a columnar rough surface topology and thus increases its contact area with the cells. It is also characterized by high charge transfer abilities, such that the amount of charge transferred in its presence is increased compared to a gold electrode as described hereinabove.

A device having a TiN layer was fabricated as described in Example 1 hereinabove, with the following addition:

After deposition of gold and chromium, and the following lift off, a second layer of AZ5214E was deposited and exposed using a specific mask. A layer of 100 nm thick TiN was thereafter deposited using Radio frequency sputtering. The electrode shape was achieved by immersing the devices in NMP overnight to allow all unexposed AZ5214E and TiN to dissolve.

FIG. 18 describes a profile measurement of TiN deposited on gold electrodes, with the “rough” areas presenting the profile for areas covered with titanium nitride and the flat area are of the gold electrodes (without TiN overlayer).

**EXAMPLE 7*****Curved devices***

The effect of the electrode’s shape, particularly curvature, on its conductance was measured.

Measurements of conductance were performed using a Keithly probe station with two probes. The conductance was measured as a function of voltage between -5 and 5 volts. All conductances were compared to the original straight unrolled device. Rolling was effected manually around cylindrical devices with varying diameters. All devices were the same as original.

Figure 19 shows the conductance of a device as shown in FIGs 2A-B, as a function of the radius of curvature. The bar graph shows that conductivity is maintained substantially the same for all curvature radii tested, this demonstrating that the device is robust and maintains its electrical properties also under strain.

It is to be noted that the polymer (e.g., photoresist) used for coating the electrode can be selected so as to impart different properties to the device. Polyimide, for example, can be used for the fabrication process in order to impart, for example, a better stretching ability to the device.

5 FIG. 20 presents a schematic illustration of an electronic element, designed to include structural features that will allow for stretching motions. The electrodes are designed so that they have a curled morphology instead of a linear one so that it can be stretched while retaining its properties.

### 10 *EXAMPLE 8*

#### *Controlling Drug release parameters*

The effect of various process parameters on the drug release properties of the drug-loaded electro-responsive hydrogels described herein, was evaluated.

All fabrication processes were the same as described hereinabove for a negative  
15 electro-responsive polymer (see, Example 5), except that after gel formation, the hydrogel were rinsed in water and acetone for several days to allow monomers to be removed and then allowed to dry in different environments (either in an ambient environment, in a chemical hood or by lyophilization). Drug loading was performed as descriebd hereinabove, after the drying. Drug release was measured as described  
20 hereinabove. Diffusion was measured similarly, but without applying any electric field. Again samples were taken every 5 minutes and measured using a nano-drop spectrophotometer, operated at 462 nm.

FIG. 21 presents comparative plots showing the effect of the drying method of the release profile of the drug from the dried hydrogel by diffusion. As shown, the  
25 drying method affects the diffusion rate, presumably due to the different pore sizes of the hydrogel in each of these methods.

FIG. 22 presents comparative plots showing the effect of the drying method of the release profile of the drug from the dried hydrogel upon electric stimulation. As shown, the drying method affects the release rate upon electric stimulation, yet, a  
30 different release pattern is observed as compared to the diffusion rate.

FIG. 23 presents a graph showing the long-term release profile of the drug from the dried hydrogel upon electric stimulation, in a hydrogel dried by lyophilization. Stimulation was applied daily on the gel and the amount of drug released was measured.

FIG. 24 presents comparative plots showing the drug release profile as a function of the applied potential, from a hydrogel dried by lyophilization.

### **EXAMPLE 8**

#### ***Swelling and drug loading***

The effect of the molar ratio of the initiator and cross-linking agent and the drying method on the swelling capacity of an electro-responsive negative polymer loaded with dopamine, was tested and the effect of the molar ratio of the initiator and cross-linking agent on the drug loading was also tested. The hydrogel was fabricated as described in Example 5 hereinabove.

#### ***Swelling degree measurements:***

After drying, two pieces from the hydrogel were cut and placed in a KCl / HCl buffer (pH 2) and at PBS1 solution to mimic physiological conditions. The Weight Swelling Fraction was calculated by the equation:

$$\text{WSF}\% = \frac{W_s - W_d}{W_d} \times 100$$

wherein  $W_d$ ,  $W_s$  is the weights of the dry hydrogel and the swelling hydrogel, respectively.

FIG. 25 presents a bar graph showing the swelling degree of the gels as a function of the molar ratio of cross linker and initiator used during gel polymerization.

FIG. 27 presents a bar graph showing the effect of the drying method on the swelling capacity of the hydrogel, and show higher swelling in the lyophilized hydrogel.

#### ***Drug loading measurements:***

The amount of drug loaded into the gel as a function of the molar ratio of the initiator and the cross-linking agent used in the polymerization was measured. The effect of the molar ratio of the initiator and cross-linking agent on the drug loading into an electro-responsive negative polymer loaded with dopamine was tested. The hydrogel was fabricated as described in Example 5 hereinabove. Drug loading was measured by

sampling the drug concentration in the loading solution during the loading process. FIG. 26 presents a bar graph showing the amount of drug loaded into the gel as a function of the initiator/cross-linking agent molar ration.

5           Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.

10           All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or  
15           identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.

## WHAT IS CLAIMED IS:

1. A scaffold device comprising:  
a three-dimensional polymeric element; and  
an electronic element being integrated with said polymeric element,  
said electronic element comprising at least one electrode being connectable to a measuring device and/or a controller, said electrode having an electrically-isolating layer deposited thereon such that a portion of said electrode remains partially uncoated in at least one location and is exposed to an environment surrounding the electrode at said at least one location.
2. The device of claim 1, wherein said electrode is exposed to said environment at a tip of said electrode.
3. The device of claim 1, wherein said electrode is exposed to said environment at a plurality of discrete locations over said electrode.
4. The device of any one of claims 1-3, wherein said thin electrically-isolating layer is an electrically-isolating polymeric layer.
5. The device of claim 4, wherein said electrically-isolating polymeric layer comprises an epoxy photoresist and/or a polyimide.
6. The device of any one of claims 1-5, wherein said thin electrically-isolating layer has a thickness that ranges from 0.1 micron to 100 microns.
7. The device of any one of claims 1-6, wherein at least one dimension of said electrode ranges from 1 micron to 1000 microns.
8. The device of any one of claims 1-6, wherein said at least one electrode has a shape of a straight line.

9. The device of any one of claims 1-6, wherein said at least one electrode has a shape of a curved line.

10. The device of claim 9, wherein said at least one electrode is elastic.

11. The device of any one of claims 1-6, wherein said at least one electrode has a generally constant conductivity as a function of a strain exhibited by said at least one electrode.

12. The device of any one of claims 1-11, wherein said electronic element comprises a plurality of electrodes, each being individually connectable to a measuring device and/or a controller, and each independently having a thin electrically-isolating layer deposited thereon such that a portion of said electrode remains partially uncoated in at least one location and is exposed to said environment surrounding the electrode at said at least one location.

13. The device of any one of claims 1-12, wherein said controller is configured for transmitting stimulation signals through the electrode.

14. The device of any one of claims 1-13, further comprising a miniature power source mounted in proximity to said electronic element.

15. The device of any one of claims 1-13, wherein said measuring device is configured for measuring signals transmitted from the polymeric element through the electrode.

16. The device of any one of claims 1-15, wherein said measuring device is configured for measuring signals transmitted from said environment through the electrode.

17. The device of any one of claims 1-16, wherein said polymeric element comprises an electrospun fibrous polymeric material.

18. The device of any one of claims 1-17, wherein said polymeric material comprises at least one of albumin, a polycaprolactone (PCL), gelatin, a poly(lactic acid) (PLA), a poly(lactic acid-co-glycolic acid) (PLGA), decellularized extracellular matrix and any combination thereof.

19. The device of claim 18, wherein said polymeric material comprises a polycaprolactone (PCL) and gelatin.

20. The device of claim 18, wherein said polymeric material comprises albumin.

21. The device of any one of claims 1-20, wherein said polymeric element comprises an electro-responsive polymeric material.

22. The device of any one of claims 1-21, further comprising cells incorporated in and/or on said polymeric element.

23. The device of claim 22, wherein said cells form a tissue.

24. The device of any one of claims 1-23, further comprising a therapeutically active agent incorporated in and/or on said polymeric element.

25. The device of claim 22, further comprising a therapeutically active agent associated with said electro-responsive polymeric material via electrostatic interactions.

26. The device of any one of claims 1-25, usable for being implanted in or on a tissue or an organ of a subject in need thereof.

27. The device of any one of claims 1-26, usable for monitoring and/or stimulating an activity and/or a function of a cell.

28. The device of claim 27, wherein said cell forms a part of a tissue.

29. The device of claim 27 or 28, wherein said cell or said tissue is incorporated in said polymeric element.

30. The device of claim 29, usable for monitoring and/or stimulating an activity and/or a function of said cell or said tissue *in vivo*.

31. The device of claim 24 or 25, usable for controlling a release of said therapeutically active agent from said polymeric element.

32. The device of claim 24 or 25, usable for determining a toxicity or an efficacy of a therapeutically active agent to a cell or tissue.

33. The device of claim 32, wherein said determining comprises:  
providing a device as defined in claim 24 or 25, in which a cell or a tissue is incorporated in the polymeric element;  
monitoring a function or activity of a cell or a tissue incorporated in the polymeric element; and  
comparing the monitored function or activity of said cell or said tissue with a function or activity of said cell or said tissue without a therapeutically active agent, thereby determining a toxicity or an efficacy of said therapeutically active agent to said cell or said tissue.

34. A system comprising the device of any one of claims 1-25 and at least one electric device selected from the group consisting of a controller and a measuring device.

35. A method of implantation, comprising:  
implanting the scaffold device of claim 22 or 23 in an organ; and  
receiving electrical signals from said cells via said electronic element.

36. The method of claim 35, wherein said scaffold device further comprises a therapeutically active agent incorporated in said polymeric element, the method



comprising transmitting stimulating signals via said electronic element so as to controllably release said therapeutically active agent from said polymeric element.

37. The method of any one of claims 35 and 36, wherein said cells are responsive to electrical stimulation and the method comprising transmitting stimulating signals via said electronic element so as to stimulate said cells.

38. A method of implantation, comprising:  
implanting a scaffold device in an organ, the scaffold device being according to claim 24 or 25; and  
transmitting stimulating signals via said electronic element so as to controllably release said therapeutically active agent from said polymeric element.

39. A method of implantation, comprising:  
implanting a scaffold device in an organ, the scaffold device being according to any of claims 22 and 23, wherein the cells are responsive to electrical stimulation; and  
transmitting stimulating signals via said electronic element so as to stimulate said cells.

40. The method according to any of claims 37 and 39, wherein said cells are cardiac cells and the organ is a myocardium.

41. The method according to claim 40, wherein said signals are selected for pacing said myocardium.

42. The method according to any of claims 38 and 39, wherein said cells are liver cells and the organ is a liver.

43. A method of treating disease or disorder caused by dysfunction in, or damage to, an excitable tissue in a subject in need thereof, the method comprising transplanting a scaffold device according to any one of claims 22-25 in the subject.

44. The method of claim 43, wherein said disorder is a cardiac disorder associated with a defective or absent myocardium, and/or characterized by abnormal cardiac rhythm.




FIG. 1A




FIG.1B




FIG. 2A

FIG. 2B

3/22




FIG. 3




FIG. 4




FIG. 5A




FIG. 5B




FIG. 6




FIG. 7A




FIG. 7B





FIG. 8




FIG. 9




FIG. 10

9/22




FIG. 11A

10/22




FIG. 11B

11/22






FIG. 12

### Derivative of No stimulation



### Derivative of 1hz stimulation






FIG. 14




FIG. 15A




FIG. 15B




FIG. 16






FIG. 17




FIG. 18

### Conductance as a function of curvature




FIG. 19




FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24




FIG. 25




FIG. 26







FIG. 27






FIG. 30



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL2014/050994

## A. CLASSIFICATION OF SUBJECT MATTER

IPC (2015.01) A61N 1/00, A61N 1/05, A61N 1/39, A61F 2/02, C23C 26/00, B05D 5/12, A61B 5/04

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC (2015.01) A61N 1/00, A61N 1/05, A61N 1/39, A61F 2/02, C23C 26/00, B05D 5/12, A61B 5/04

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Databases consulted: THOMSON INNOVATION, Esp@cenet, Google Patents, Google Scholar

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2010211172 A1 Bellamkonda et al. 19 Aug 2010 (2010/08/19) (The whole document especially abstract, Figs.1A, 1B, 3C, 5A, 5B, 7-10, 15A, 15B, paragraphs 55-86, 94, 106-112, 120-121)	1-5,8-31,34-39,43
Y	(The whole document especially abstract, Figs.1A, 1B, 3C, 5A, 5B, 7-10, 15A, 15B, paragraphs 55-86, 94, 106-112, 120-121)	6,7,40-42,44
X	US 2006136028 A1 Ross et al. 22 Jun 2006 (2006/06/22) (The whole document especially abstract, Figs. 2, 3, 4A-C, 5-8, paragraphs 7-11, 73-76, 118-119, 168-180, 190-200).	1-5,8-31
Y	(The whole document especially abstract, Figs. 2, 3, 4A-C, 5-8, paragraphs 7-11, 73-76, 118-119, 168-180, 190-200).	5-44
X	US 2011087315 A1 Richardson-Burns et al. 14 Apr 2011 (2011/04/14) (The whole document especially abstract, Figs. 2, 4A-B, 5, 8, 9, paragraphs 3, 11-14, 53, 55, 73, 84, 103, 115, 117, 155, 178, 52, 56, 78, 138, 142, 145-160, 41, 80, 81, 127).	1,2

 Further documents are listed in the continuation of Box C. See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

16 Mar 2015

Date of mailing of the international search report

22 Mar 2015

Name and mailing address of the ISA:

Israel Patent Office  
Technology Park, Bldg.5, Malcha, Jerusalem, 9695101, Israel  
Facsimile No. 972-2-5651616

Authorized officer

NIMER Emad

Telephone No. 972-2-5657801

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL2014/050994

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	(The whole document especially abstract, Figs. 2, 4A-B, 5, 8, 9, paragraphs 3, 11-14, 53, 55, 73, 84, 103, 115, 117, 155, 178, 52, 56, 78, 138, 142, 145-160, 41, 80, 81, 127).	21,25,31,40-42
X	US 2007060815 A1 Martin et al. 15 Mar 2007 (2007/03/15) (The whole document especially abstract, Fig. 4A-C, 5, 6A-B, paragraphs 3, 7-9, 64-66, 70-81, 87-93, 162, 164, 173, 174).	1,2
Y	(The whole document especially abstract, Fig. 4A-C, 5, 6A-B, paragraphs 3, 7-9, 64-66, 70-81, 87-93, 162, 164, 173, 174).	21,25,31,40-42
X	US 2008208358 A1 Bellamkonda et al. 28 Aug 2008 (2008/08/28) (The whole document especially abstract, Figs. 1-5, paragraphs 6, 28, 31, 41, 57).	1,2
Y	(The whole document especially abstract, Figs. 1-5, paragraphs 6, 28, 31, 41, 57).	3-44
X	WO 2013086502 A1 Ingber et al. 13 Jun 2013 (2013/06/13) (The whole document especially abstract, paragraphs 3, 15, 20, 24, 25, 37, 40, 45, 58, 64, 65, 90, 100, 111-114, 121-123, 128—132, 137, 152, 165, 172, 183, 186, Figs. 3A-3C, 8, 12, 13 ).	1,2
Y	(The whole document especially abstract, paragraphs 3, 15, 20, 24, 25, 37, 40, 45, 58, 64, 65, 90, 100, 111-114, 121-123, 128—132, 137, 152, 165, 172, 183, 186, Figs. 3A-3C, 8, 12, 13 ).	32,33
P,X	"Organic electrode coatings for next-generation neural interfaces" Aregueta-Robles et al. Vol. 7, Pages 1-15. 01 May 2014 (2014/05/01) (The whole document especially abstract, Fig. 1).	1,2
P,Y	(The whole document especially abstract, Fig. 1).	3-44
Y	US 2009248113 A1 Nimer et al. 01 Oct 2009 (2009/10/01) (paragraphs 134-136, Figs. 1, 3).	6,7

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No. PCT/IL2014/050994
--

Patent document cited search report	Publication date	Patent family member(s)	Publication Date
US 2010211172 A1	19 Aug 2010	US 2010211172 A1	19 Aug 2010
		EP 2131919 A2	16 Dec 2009
		EP 2131919 A4	20 Oct 2010
		WO 2008122044 A2	09 Oct 2008
		WO 2008122044 A3	30 Dec 2009
US 2006136028 A1	22 Jun 2006	US 2006136028 A1	22 Jun 2006
		US 8060219 B2	15 Nov 2011
US 2011087315 A1	14 Apr 2011	US 2011087315 A1	14 Apr 2011
		AU 2006284625 A1	08 Mar 2007
		AU 2006284625 B2	04 Apr 2013
		CA 2621174 A1	08 Mar 2007
		EP 1931248 A2	18 Jun 2008
		EP 1931248 A4	07 Apr 2010
		EP 2514359 A2	24 Oct 2012
		EP 2514359 A3	19 Nov 2014
		JP 2009506836 A	19 Feb 2009
		US 2007060815 A1	15 Mar 2007
		US 8005526 B2	23 Aug 2011
		US 2011257504 A1	20 Oct 2011
		WO 2007028003 A2	08 Mar 2007
		WO 2007028003 A3	11 Oct 2007
		WO 2007028003 B1	29 Nov 2007
WO 2011127166 A2	13 Oct 2011		
WO 2011127166 A3	16 Feb 2012		
US 2007060815 A1	15 Mar 2007	US 2007060815 A1	15 Mar 2007
		US 8005526 B2	23 Aug 2011
		AU 2006284625 A1	08 Mar 2007
		AU 2006284625 B2	04 Apr 2013

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.  
PCT/IL2014/050994

Patent document cited search report	Publication date	Patent family member(s)	Publication Date
		CA 2621174 A1	08 Mar 2007
		EP 1931248 A2	18 Jun 2008
		EP 1931248 A4	07 Apr 2010
		EP 2514359 A2	24 Oct 2012
		EP 2514359 A3	19 Nov 2014
		JP 2009506836 A	19 Feb 2009
		US 2011087315 A1	14 Apr 2011
		US 2011257504 A1	20 Oct 2011
		WO 2007028003 A2	08 Mar 2007
		WO 2007028003 A3	11 Oct 2007
		WO 2007028003 B1	29 Nov 2007
		WO 2011127166 A2	13 Oct 2011
		WO 2011127166 A3	16 Feb 2012
US 2008208358 A1	28 Aug 2008	US 2008208358 A1	28 Aug 2008
		US 8652215 B2	18 Feb 2014
		AU 2006220565 A1	14 Sep 2006
		CA 2599946 A1	14 Sep 2006
		EP 1855618 A2	21 Nov 2007
		JP 2008536539 A	11 Sep 2008
		WO 2006096791 A2	14 Sep 2006
		WO 2006096791 A3	14 Aug 2008
WO 2013086502 A1	13 Jun 2013	WO 2013086502 A1	13 Jun 2013
		US 2014342445 A1	20 Nov 2014
US 2009248113 A1	01 Oct 2009	US 2009248113 A1	01 Oct 2009
		US 8010208 B2	30 Aug 2011
		EP 1888161 A2	20 Feb 2008
		EP 1888161 A4	29 Apr 2009
		WO 2006131912 A2	14 Dec 2006

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.  
PCT/IL2014/050994

Patent document cited search report	Publication date	Patent family member(s)	Publication Date
		WO 2006131912 A3	07 Jun 2007